On this page
Quick Reference
Overview and Recommendations
Background
- •Recognize Addison disease as the primary form of adrenal insufficiency (PAI), where the pathology resides within the adrenal glands themselves, distinguishing it from secondary (pituitary) or tertiary (hypothalamic) failure. This distinction is critical because PAI involves a global loss of all three adrenal steroid layers, whereas secondary forms typically preserve mineralocorticoid function.
- •Identify autoimmune adrenalitis (AAD) as the etiology in 80-90% of cases in Western countries, often occurring as part of (APS) Type 1 or Type 2. In these patients, the immune system targets the 21-hydroxylase enzyme, leading to progressive lymphocytic infiltration and cortical atrophy.
- •Consider non-autoimmune etiologies in specific contexts, such as infectious adrenalitis (tuberculosis, CMV in HIV/AIDS), bilateral adrenal hemorrhage (often associated with ), or genetic disorders like X-linked (X-ALD) in young males.
- •Understand the physiological impact of hormonal loss, where cortisol deficiency leads to impaired gluconeogenesis and hypotension, while aldosterone deficiency causes renal salt wasting, , and . The loss of adrenal androgens is most clinically significant in women, manifesting as a loss of axillary/pubic hair and reduced libido.
- •Anticipate the risk of an adrenal crisis (AC), which occurs at a rate of 5-10 events per 100 patient-years. This is an endocrine emergency triggered by infection, surgery, or trauma, requiring immediate recognition to prevent circulatory collapse and death.
Evaluation
- •Suspect Addison disease in any patient presenting with the classic triad of profound fatigue, unexplained weight loss, and hyperpigmentation. Hyperpigmentation is most visible in skin creases, recent scars, and the buccal mucosa, resulting from high ACTH levels cross-reacting with melanocortin-1 receptors.
- •Ask specifically about salt craving, which is a hallmark of mineralocorticoid deficiency, and gastrointestinal symptoms such as nausea, vomiting, or vague abdominal pain that may mimic an acute abdomen or eating disorder.
- •Examine for orthostatic hypotension, defined as a systolic drop >20 mmHg or diastolic drop >10 mmHg upon standing, reflecting the volume depletion characteristic of aldosterone deficiency.
- •Order a morning (8 AM) serum cortisol and plasma ACTH as the initial screening step. A cortisol level < 3 mcg/dL (80 nmol/L) is highly suggestive of insufficiency, while a level > 15 mcg/dL (414 nmol/L) generally rules it out.
- •Confirm the diagnosis with a high-dose (250 mcg) ACTH stimulation test (Cosyntropin test). Administer 250 mcg of ACTH IV or IM and measure cortisol at 30 and 60 minutes; a peak cortisol response < 18 mcg/dL (500 nmol/L) confirms adrenal insufficiency.
- •Differentiate primary from secondary insufficiency by checking the baseline ACTH level. In Addison disease, ACTH will be significantly elevated (often > 100 pg/mL), whereas it will be low or inappropriately normal in pituitary-related failure.
- •Evaluate for mineralocorticoid deficiency by measuring plasma renin activity and aldosterone. In PAI, you will typically find elevated renin with low or undetectable aldosterone levels.
- •Screen for common electrolyte derangements, specifically (found in 90% of patients) and (found in 65% of patients), along with hypoglycemia and mild metabolic acidosis.
- •Determine the etiology by testing for 21-hydroxylase antibodies (anti-21-OH). If positive, the diagnosis is autoimmune adrenalitis; if negative, further workup is required.
- •Perform a CT scan of the adrenal glands if antibodies are negative or if an infectious/hemorrhagic cause is suspected. Look for adrenal calcifications (suggestive of tuberculosis) or enlarged, hemorrhagic glands.
- •Screen male patients with negative antibodies for X-linked adrenoleukodystrophy by measuring very-long-chain fatty acids (VLCFAs), as PAI may be the only presenting sign before neurological symptoms emerge.
Management
- •Administer glucocorticoid replacement as the cornerstone of therapy, typically using Hydrocortisone 15–25 mg daily, divided into two or three doses (e.g., 10 mg on waking, 5 mg at lunch, and 2.5 mg in the late afternoon) to mimic the natural circadian rhythm.
- •Use longer-acting glucocorticoids like Prednisone 3–5 mg once daily as an alternative for patients with poor compliance or those who experience "wear-off" symptoms between hydrocortisone doses, though monitoring for over-replacement is more difficult.
- •Initiate mineralocorticoid replacement with Fludrocortisone 0.05–0.2 mg daily to maintain normovolemia and normal potassium levels. Unlike glucocorticoids, the dose does not usually need to be increased during minor illness.
- •Educate the patient on "sick day rules," which involve doubling or tripling the oral glucocorticoid dose during febrile illnesses or minor procedures to prevent progression to an adrenal crisis.
- •Provide an emergency injection kit containing 100 mg of Hydrocortisone (e.g., Solu-Cortef) and train the patient and their family on IM injection techniques for use during severe vomiting, trauma, or altered consciousness.
- •Manage an acute adrenal crisis immediately with 100 mg IV Hydrocortisone bolus, followed by 200 mg per 24 hours (either as a continuous infusion or 50 mg every 6 hours), alongside aggressive isotonic saline resuscitation.
- •Avoid using Dexamethasone for chronic maintenance if possible, as its high potency and lack of mineralocorticoid activity increase the risk of Cushingoid side effects and electrolyte imbalances.
- •Consider DHEA replacement (25–50 mg daily) in women who report persistently low libido, impaired mood, or low energy despite optimized glucocorticoid and mineralocorticoid therapy.
- •Adjust doses during pregnancy by increasing the hydrocortisone dose by 20–50% during the third trimester to account for increased cortisol-binding globulin and physiological demand.
- •Implement perioperative stress dosing: for major surgery, administer 100 mg IV Hydrocortisone at induction, followed by 200 mg/24 hours for 48–72 hours, tapering rapidly back to maintenance as the patient recovers.
- •Monitor for signs of over-replacement, such as weight gain, insomnia, peripheral edema, or hypertension, and adjust doses to the lowest effective amount to preserve bone mineral density.
- •Refer all patients to an endocrinologist for long-term management and ensure they wear a medical alert bracelet or carry a steroid emergency card at all times.
- •Discharge patients only after they demonstrate the ability to self-administer emergency injections and can articulate the specific triggers for seeking emergency care.
Board Review — High Yield
- •Hyperpigmentation — Caused by high ACTH cross-reacting with MC1R receptors on melanocytes.
- •21-hydroxylase antibodies — The most specific marker for autoimmune adrenalitis in adults.
- •Hyponatremia and Hyperkalemia — The classic electrolyte pattern of primary (but not secondary) adrenal insufficiency.
- •Salt Craving — A specific symptom of mineralocorticoid deficiency found in PAI.
- •Adrenal Crisis — Presents as refractory shock; treat with IV fluids and 100mg IV Hydrocortisone immediately.
- •X-linked Adrenoleukodystrophy — Consider in young males with PAI and negative antibodies; check VLCFAs.
- •Waterhouse-Friderichsen Syndrome — Acute adrenal failure due to bilateral hemorrhage, often from Neisseria meningitidis.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸Addison disease is defined as primary adrenal insufficiency, where the adrenal cortex fails to produce adequate glucocorticoids and mineralocorticoids [4, 10].
- ▸Etiological classification is essential; for instance, X-linked adrenoleukodystrophy (X-ALD) must be ruled out in males presenting with 'Addison's-only' symptoms to prevent rapid neurological decline [6].
- ▸Adrenal crisis is the most acute phase of the disease, occurring at a rate of 5-10 per 100 patient-years and requiring immediate stabilization to prevent mortality [7, 9].
Addison disease is a chronic endocrine disorder characterized by the failure of the adrenal cortex to produce sufficient steroid hormones, specifically glucocorticoids and often mineralocorticoids, due to direct damage or dysfunction of the adrenal glands themselves [4]D[10]D. This condition represents the primary form of adrenal insufficiency (PAI), distinguishing it from secondary or tertiary forms caused by pituitary or hypothalamic failure, respectively [4]D.
Synonyms and Alternate Names
Addison disease is frequently referred to by several names depending on the clinical context and etiology:
- Primary Adrenal Insufficiency (PAI): The broad physiological term for adrenal gland failure [10]D.
- Autoimmune Adrenalitis (AAD): The specific term used when the condition is caused by an autoimmune attack on the adrenal cortex, which is the most prevalent cause in the developed world [4]D.
- Chronic Adrenocortical Insufficiency: A descriptive term for the long-term nature of the hormonal deficit.
- Addison's-only Phenotype: A specific clinical presentation of X-linked adrenoleukodystrophy (X-ALD) where adrenal failure is the sole initial manifestation [6]C.
Key Definitions of Phases and Stages
The progression of Addison disease can be categorized into distinct clinical phases, which are critical for determining the urgency of intervention:
- Subclinical/Prodromal Phase: Characterized by the presence of adrenal cortex autoantibodies (ACAs) or genetic markers (e.g., ABCD1 mutations) without overt cortisol deficiency [4]D[6]C. Patients may be asymptomatic but are at high risk for progression.
- Progressive Phase: A period of declining adrenal reserve where nonspecific symptoms (fatigue, weight loss) and cutaneous manifestations, such as hyperpigmentation, begin to appear [14]D.
- Overt Insufficiency: The stage where baseline cortisol production is inadequate to meet physiological demands, often confirmed by a high-dose corticotropin stimulation test [12]D.
- Adrenal Crisis (AC): A life-threatening physiological disturbance occurring at a rate of 5-10 events per 100 patient-years [9]D. It is an endocrine emergency characterized by hemodynamic instability and potential death if untreated [7]D.
- Recovery Phase: While spontaneous recovery of adrenal function is rare in AAD, it has been described [4]D. In most cases, recovery refers to the stabilization of the patient following an acute crisis through hormone replacement.
Etiological Classification
Classification is primarily based on the underlying mechanism of adrenal destruction. Distinguishing between these types is vital because genetic causes like X-ALD require different long-term monitoring than autoimmune forms [3]D[6]C.
Protocol for Etiological Classification
Step 1 → Confirm Primary Adrenal Insufficiency by demonstrating inappropriately low cortisol production and elevated ACTH [4]D[8]D. Step 2 → Test for Adrenal Cortex Autoantibodies (ACAs) to identify Autoimmune Adrenalitis [4]D. Step 3 → If ACAs are negative, perform genetic screening (e.g., Very Long Chain Fatty Acids for X-ALD in males or STAR gene sequencing in infants) [2][3]D[6]C. Step 4 → Utilize imaging (CT/MRI) to evaluate for adrenal hemorrhage, especially in patients with Antiphospholipid Syndrome (APS), or to identify adrenal incidentalomas >1 cm [1][13]D.
Comparative Classification of Variants
| Variant Name | Key Distinguishing Feature | Associated Markers/Antibodies |
|---|---|---|
| Autoimmune Adrenalitis (AAD) | Most common cause; associated with other autoimmune diseases like [4]D[11]D. | Adrenal cortex autoantibodies (ACAs) [4]D |
| X-linked Adrenoleukodystrophy (X-ALD) | Accumulation of very long chain fatty acids (VLCFAs); can present as "Addison's-only" [3]D[6]C. | ABCD1 gene mutations [3]D |
| Lipoid (LCAH) | Severe defect in all adrenal and gonadal steroidogenesis [2]. | STAR protein deficiency [2] |
| APS-Associated Adrenal Hemorrhage | Vascular destruction of the adrenals; often bilateral [1]. | Antiphospholipid antibodies (aPL) [1] |
| Iatrogenic (ICI-induced) | Rare immune-related adverse event (irAE) from cancer therapy [5]D. | History of Immune Checkpoint Inhibitors [5]D |
| Traumatic Adrenal Insufficiency | Occurs following severe traumatic brain injury (TBI) [12]D. | Baseline cortisol <15 µg/dL (414 nmol/L) [12]D |
| Variant | Mechanism | Clinical Context |
|---|---|---|
| Autoimmune | Lymphocytic infiltration | Associated with (aOR 1.45) [11]D |
| Genetic (X-ALD) | Peroxisomal disorder | Myelopathy and peripheral neuropathy [3]D |
| Genetic (LCAH) | Steroidogenic defect | STAR deficiency; Group A, B, or C phenotypes [2] |
| Vascular | Adrenal hemorrhage | Antiphospholipid Syndrome (APS) [1] |
| Iatrogenic | Immune-related AE | Incidence ≥1/10,000 to <1/1000 in ICI patients [5]D |
Epidemiology and Risk Factors
- ▸Autoimmune Addison's disease (AAD) is the leading cause of PAI in adults, with nearly 50% of patients having at least one other autoimmune comorbidity, most commonly thyroid disease [25, 41].
- ▸Iatrogenic PAI is an emerging concern in oncology, with immune checkpoint inhibitors (ICIs) causing PAI in approximately 1.03% of treated patients [36].
- ▸Pediatric PAI is most frequently genetic, with the highest incidence occurring in the first year of life (up to 4.0 per 100,000 person-years in males) [34].
Primary adrenal insufficiency (PAI), historically known as , is a rare but life-threatening condition characterized by the failure of the adrenal cortex to produce sufficient steroid hormones. The of PAI varies significantly by age, geography, and underlying etiology, with autoimmune destruction predominating in developed nations and genetic or iatrogenic causes being more prevalent in pediatric and oncological populations [25]D[34]D.
Global Incidence and Prevalence
The incidence of PAI in the general population is relatively low, but it carries significant morbidity if undiagnosed. In pediatric populations, the incidence is highest during the first year of life, with rates of 2.7 per 100,000 person-years in females and 4.0 per 100,000 person-years in males [34]D. This early peak is largely driven by (CAH). In adults, autoimmune Addison's disease (AAD) is the most common form in Western countries [25]D. Specific genetic conditions also contribute to the global burden; for instance, X-linked adrenoleukodystrophy (X-ALD) has an estimated birth prevalence of 1 in 17,000 subjects, regardless of ethnic or regional background [29]D.
Demographic Distribution
Demographic patterns in PAI are heavily influenced by the specific etiology:
- Sex: AAD shows a strong female predilection, with women being more frequently affected than men [25]D. Conversely, certain genetic forms like X-ALD primarily affect males due to their X-linked inheritance [29]D. In childhood PAI, males represent approximately 64% of cases, likely due to the higher frequency of X-linked disorders and early-presenting CAH [34]D.
- Age: The onset of PAI can occur at any age. Genetic causes such as CAH, Triple A syndrome, and CPOX deficiency typically present in infancy or childhood [23]C[26]D[39]D. AAD usually presents in adulthood, often between the third and fifth decades. Iatrogenic PAI, particularly that induced by (ICIs), is increasingly recognized in older adults treated for malignancies [40]D.
Etiological Risk Factors
Autoimmune Susceptibility
Autoimmune Addison's disease is primarily a T-cell mediated disorder [38]D. Genetic susceptibility is highly linked to the human leucocyte antigen (HLA) region, specifically HLA-DR3 and DR4 [38]D. Recent studies have also identified copy number variations in the CYP21A2 gene as a potential risk factor for AAD [33]D. Patients with AAD are at high risk for other autoimmune conditions; approximately 48% of patients also have autoimmune thyroid disease, and 6-10% of women with AAD develop (POI) [25]D[41]D. Polygenic risk scores (PRS) are now being developed to help differentiate AAD from other forms of PAI, as AAD patients typically score 1.5 standard deviations higher on these scales than healthy controls [35]D.
Iatrogenic and Medication-Induced Risk
The landscape of PAI is shifting due to the widespread use of novel oncological therapies.
- Immune Checkpoint Inhibitors (ICIs): The incidence of ICI-associated PAI is approximately 1.03% [36]D. The risk is higher in patients receiving combination therapy (e.g., TKI + ICI) compared to monotherapy [27]D.
- Lenvatinib: This multi-kinase inhibitor, used for radioiodine-refractory thyroid cancer, is associated with an under-recognized risk of cortisol deficiency, which may contribute to the high rates of fatigue reported by these patients [24]D[42]D.
- Radiotherapy: Stereotactic ablative radiotherapy (SAbR) for adrenal metastases carries a 14% overall risk of PAI. This risk escalates to 44% in patients receiving bilateral SAbR or those with a prior unilateral adrenalectomy [28]D.
Genetic and Environmental Factors
In specific regions like Sudan, CAH and Triple A syndrome are the most common genetic causes in children [26]D. Rare variants, such as biallelic inactivating CPOX mutations, can cause childhood-onset PAI associated with differences in sexual differentiation [23]C. While environmental factors are less studied in humans, data from high-risk canine models suggest that lifestyle and environmental exposures may play a role in multifactorial PAI development [21].
Comorbidities and Temporal Trends
Patients with PAI face long-term health risks beyond adrenal insufficiency itself. There is an increased risk of major osteoporotic fractures (7.1 per 1,000 person-years) compared to matched controls [18]. Furthermore, patients with AAD exhibit altered biomarkers for cardiovascular disease and inflammation, suggesting a higher baseline cardiovascular risk [30]D. During the pandemic, patients with AAD were found to be at increased risk for severe infection and hospitalization [19]. In CAH populations, there is a significantly higher prevalence of depressive and anxiety disorders compared to the general population [32]D.
Protocol for Epidemiological Risk Assessment
Step 1 → Identify High-Risk Populations: Screen patients with existing autoimmune endocrinopathies (especially thyroid disease) or those undergoing treatment with ICIs, lenvatinib, or adrenal radiotherapy [24]D[28]D[36]D[41]D.
Step 2 → Genetic and Antibody Screening: In pediatric cases or suspected AAD, utilize 21-hydroxylase antibody testing and genetic panels (e.g., ABCD1 for X-ALD, CYP21A2 for CAH) to define etiology [6]C[33]D[35]D.
Step 3 → Monitor for Clinical Triggers: Educate high-risk patients on the signs of adrenal crisis, particularly during periods of physiological stress such as infection, fasting (e.g., Ramadan), or pregnancy [15][16][17][19].
| Risk Factor | Association / Incidence | Evidence Level |
|---|---|---|
| Female Sex | Higher risk for Autoimmune Addison's Disease (AAD) | 5 [25]D |
| HLA-DR3/DR4 | Major genetic susceptibility loci for AAD | 5 [38]D |
| ICI Therapy | ~1.03% incidence of new-onset PAI | 5 [36]D |
| Bilateral Adrenal SAbR | 44% risk of developing PAI | 5 [28]D |
| Turner Syndrome | Increased prevalence of autoimmune disorders | 5 [31]D |
| Autoimmune Thyroid Disease | Present in 48% of AAD patients | 5 [41]D |
| Lenvatinib Treatment | Under-recognized cause of cortisol deficiency | 5 [24]D |
Etiology and Triggering Factors
- ▸Autoimmune adrenalitis is the most common cause in adults (80-90%), while Congenital Adrenal Hyperplasia is most common in children.
- ▸X-linked Adrenoleukodystrophy (X-ALD) must be ruled out in all male patients with PAI of unknown etiology by measuring very long-chain fatty acids (VLCFA).
- ▸Bilateral adrenal hemorrhage is a rare but life-threatening cause often associated with Antiphospholipid Syndrome (APS) or acute physiological stress.
Primary adrenal insufficiency (PAI), historically termed , represents the clinical end-stage of a destructive process involving the adrenal cortex [48]C. This destruction results in the inadequate production of essential steroid hormones, predominantly cortisol and aldosterone [65]D. The etiology of PAI varies significantly by age, geographic region, and underlying immune status, with autoimmune destruction predominating in developed nations and infectious or genetic causes being more prevalent in other contexts [44]D[47]D.
Autoimmune Adrenalitis
Autoimmune adrenalitis is the leading cause of PAI in adults, accounting for 80% to 90% of cases in high-income settings [44]D[47]D. The pathogenic mechanism involves the immune system erroneously targeting the adrenal cortex, leading to progressive lymphocytic infiltration and atrophy [65]D. This may occur as an isolated condition or as part of an (APS).
- APS Type 2: This is characterized by the association of Addison disease with Type 1 Diabetes Mellitus and/or autoimmune thyroid disease (e.g., ) [53]C.
- Clinical Pearl: In pediatric cases, autoimmune adrenalitis is rarer than in adults but must be considered if other autoimmune markers are present [53]C.
Infectious Triggers
Infections remain a significant global cause of adrenal destruction, particularly in tuberculosis-endemic regions [50]C.
- Adrenal Tuberculosis: Mycobacterium tuberculosis causes caseating granulomatous inflammation within the adrenal glands [50]C. It may present as bilateral adrenal masses with calcifications [50]C. Even in modern settings, adrenal involvement in TB is associated with increased mortality [55].
- HIV/AIDS: PAI is a common endocrine complication in patients with AIDS, often triggered by opportunistic infections such as Cytomegalovirus (CMV) or TB [43]C. Diagnosis is frequently delayed due to non-specific symptoms like fatigue and weight loss [43]C.
- : Emerging evidence suggests that SARS-CoV-2 can trigger PAI through direct viral damage, immune-mediated injury, or bilateral adrenal infarction/hemorrhage, particularly in the context of catastrophic antiphospholipid syndrome [52]C[66]D.
- Non-Tuberculous Mycobacteria: Rare cases have been linked to Mycobacterium abscessus infection, especially in patients with comorbid conditions like Type 2 Diabetes Mellitus [54]C.
Genetic and Metabolic Disorders
Genetic causes are the most frequent etiology in children, with (CAH) being the primary driver [46]D[47]D.
- X-linked Adrenoleukodystrophy (X-ALD): Caused by mutations in the ABCD1 gene, which encodes the adrenoleukodystrophy protein (ALDP) [29]D[60]D. Deficiency leads to impaired peroxisomal β-oxidation and the accumulation of very long-chain fatty acids (VLCFA) in the adrenal cortex and nervous system [29]D[58]D. It affects approximately 1 in 17,000 individuals [29]D. PAI is often the first clinical sign in young boys [64]C.
- Pseudo-neonatal Adrenoleukodystrophy (PNALD): A rare peroxisomal disorder caused by biallelic ACOX1 mutations, leading to VLCFA accumulation and early-onset PAI [51]C[62]C.
- Other Genetic Syndromes: Rare forms include adrenal dysgenesis, ACTH resistance, and other defects in steroidogenesis [46]D.
Vascular and Hemorrhagic Causes
Bilateral adrenal hemorrhage (AH) or infarction can lead to acute adrenal crisis and permanent PAI [59]D.
- Antiphospholipid Syndrome (APS): A critical cause of bilateral AH, often associated with persistent antiphospholipid antibodies [1][57]C. It may be triggered by surgery, infection, or trauma [1][48]C.
- Critical Illness and Trauma: AH is discovered incidentally in 42% of cases, but can be triggered by postoperative complications (41%), trauma (30%), or coagulopathy [59]D.
Pharmacological and Iatrogenic Causes
Certain medications can inhibit adrenal steroidogenesis or increase cortisol metabolism.
- Steroidogenesis Inhibitors: High doses of azole antifungals, specifically Posaconazole, can disrupt the steroid synthesis pathway, leading to low morning cortisol and elevated ACTH [44]D[63]C.
- Surgical Removal: Bilateral adrenalectomy for other conditions results in immediate PAI [44]D.
Protocol for Etiological Investigation
When PAI is confirmed (low cortisol, high ACTH), the following steps should be taken to determine the etiology:
- Step 1: Screen for 21-hydroxylase antibodies to evaluate for autoimmune adrenalitis [44]D.
- Step 2: In males (especially children/young adults) with negative antibodies, measure plasma VLCFAs to screen for X-ALD [6]C[61]D.
- Step 3: Perform adrenal imaging (CT or Ultrasound) to look for calcifications (TB), hemorrhage (APS), or masses (metastasis/infection) [50]C[57]C[59]D.
- Step 4: If imaging shows masses and infection is suspected, consider ultrasound-guided biopsy for histopathological analysis [50]C.
| Cause | Category | Frequency | Associated Subtype | Key Reference |
|---|---|---|---|---|
| Autoimmune Adrenalitis | Autoimmune | 80-90% (Adults) | Isolated or APS Type 1/2 | [44]D[47]D[53]C |
| Congenital Adrenal Hyperplasia | Genetic | Most common (Children) | 21-hydroxylase deficiency | [46]D[47]D |
| X-linked Adrenoleukodystrophy | Metabolic/Genetic | 1 in 17,000 births | Addison-only, AMN, Cerebral | [29]D[60]D[61]D |
| Tuberculosis | Infectious | Common in endemic areas | Adrenal TB | [50]C[55] |
| Adrenal Hemorrhage | Vascular | Rare (<5%) | Antiphospholipid Syndrome (APS) | [1][57]C[59]D |
| HIV/AIDS | Infectious | Variable | CMV, TB, Fungal | [43]C |
| Posaconazole/Azoles | Drug-induced | Rare | Pharmacological inhibition | [44]D[63]C |
| ACOX1 Deficiency | Genetic | Ultra-rare | Pseudo-neonatal ALD | [51]C[62]C |
Pathophysiology
- ▸The primary autoimmune target is the 21-hydroxylase enzyme, with destruction mediated by cytolytic CD8+ T cells and a Th1-dominant cytokine environment.
- ▸Clinical symptoms typically emerge only after 90% of the adrenal cortex is destroyed, following a subclinical phase of progressive atrophy.
- ▸Hyperpigmentation results from the loss of negative feedback, leading to excessive POMC production and subsequent cleavage into ACTH and α-MSH.
The pathophysiology of Addison disease, or primary adrenal insufficiency (PAI), involves the progressive destruction or functional failure of the adrenal cortex, leading to a global deficiency of glucocorticoids, mineralocorticoids, and adrenal androgens [44]D[89]D. Unlike secondary adrenal insufficiency, which is a failure of the pituitary to secrete adrenocorticotropic hormone (ACTH), PAI is characterized by the inability of the adrenal glands to respond to ACTH stimulation [89]D. This failure triggers a loss of negative feedback, resulting in a compensatory but ineffective overproduction of pro-opiomelanocortin (POMC) and its derivatives [44]D.
Autoimmune Adrenalitis: The Cellular Mechanism
In industrialized nations, autoimmune destruction accounts for the majority of cases [75]D[80]D. The process is a classic organ-specific autoimmune attack where the adrenal cortex is infiltrated by lymphocytes, a condition known as autoimmune adrenalitis [75]D.
Step 1: Antigen Exposure and Recognition The primary target antigen is 21-hydroxylase (21-OH), an essential enzyme in the steroidogenic pathway located within the endoplasmic reticulum of adrenocortical cells [68][80]D. While autoantibodies against 21-OH are diagnostic markers found in >90% of patients, they are not the primary mediators of tissue destruction [68]. Instead, the adrenocortical cell itself acts as an active player, potentially presenting antigens via MHC molecules in response to environmental triggers [90]D.
Step 2: T-Cell Activation and Th1 Dominance The destruction is primarily mediated by cellular immunity. High frequencies of 21-hydroxylase-specific CD8+ and CD4+ T cells are found in the peripheral blood of patients [68]. These CD8+ T cells are cytolytic, directly attacking the steroid-producing cells of the zona fasciculata and zona glomerulosa [68]. The inflammatory environment is characterized by a Th1-driven chemokine profile, specifically elevated levels of CXCL10 and CXCL11, which facilitate the trafficking of leukocytes to the adrenal glands [69].
Step 3: Progressive Cortical Atrophy As the immune attack persists, the adrenal cortex undergoes progressive atrophy. Clinical symptoms typically do not manifest until approximately 90% of the adrenal cortical tissue has been destroyed [80]D. During this subclinical phase, patients may have detectable 21-OH antibodies but maintain normal basal cortisol levels, only showing impairment during dynamic stimulation tests [88]D.
Molecular and Genetic Susceptibility
The transition from health to autoimmunity is governed by a complex interplay of genetic and environmental factors [76]D[90]D.
- Immunogenetics: Specific HLA genotypes (e.g., HLA-DR3-DQ2 and DR4-DQ8) significantly increase susceptibility [75]D.
- Vitamin D Modulation: The vitamin D receptor (VDR) and the enzyme 1α-hydroxylase (CYP27B1) are expressed on B cells, T cells, and antigen-presenting cells [79]D. Vitamin D acts as an immunomodulator; its deficiency or VDR polymorphisms may impair the immune system's ability to maintain self-tolerance [79]D.
- Environmental Triggers: Viral infections are hypothesized to trigger the process via molecular mimicry or bystander activation, though specific causative agents remain elusive [76]D.
Non-Autoimmune Pathogenic Pathways
While autoimmunity is common in adults, other mechanisms prevail in pediatric and specific clinical populations:
- Metabolic Accumulation (X-ALD): In X-linked adrenoleukodystrophy, mutations in the ABCD1 gene lead to a deficiency in the ALD protein (ALDP), which is required for the peroxisomal β-oxidation of very-long-chain fatty acids (VLCFA) [29]D[3]D. These VLCFAs accumulate in the adrenal cortex, exerting a direct toxic effect on the cell membranes and interfering with ACTH receptor signaling [3]D[29]D.
- Vascular Insufficiency: In Antiphospholipid Syndrome (APS), the pathogenesis involves intra-adrenal vascular thrombosis or hemorrhage [81]C[82]C. The unique vascular supply of the adrenal gland—multiple small arteries draining into a single vein—makes it highly susceptible to hemorrhagic infarction during states of hypercoagulability or stress [81]C.
- Mitochondrial Dysfunction: Variants in genes like TXNRD2 impair the reactive oxygen species (ROS) detoxification system [83]C. Because steroidogenesis is energy-intensive and generates high levels of ROS, mitochondrial failure leads to oxidative stress and subsequent adrenocortical cell death [83]C.
Consequences of Hormonal Loss
The clinical manifestations of Addison disease are a direct result of the specific hormones lost from the three layers of the adrenal cortex:
- Glucocorticoid Deficiency (Zona Fasciculata): Loss of cortisol leads to impaired gluconeogenesis and increased insulin sensitivity, causing hypoglycemia [44]D. It also results in the elevation of GDF15, a stress-induced hormone that acts on the hindbrain to induce anorexia, nausea, and weight loss [67].
- Mineralocorticoid Deficiency (Zona Glomerulosa): Loss of aldosterone leads to renal salt wasting (sodium loss) and potassium retention [74]D. This results in hypovolemia, hyponatremia, and hyperkalemia, which can progress to life-threatening circulatory collapse [44]D[84]C.
- Androgen Deficiency (Zona Reticularis): In females, the adrenals are the primary source of androgens. Deficiency leads to the loss of axillary and pubic hair and reduced libido [72]D[74]D.
Feedback Loop Disruption and Hyperpigmentation
The hallmark of PAI is the disruption of the hypothalamic-pituitary-adrenal (HPA) axis. In a healthy state, cortisol inhibits the secretion of CRH and ACTH. In Addison disease, the lack of cortisol removes this inhibition, leading to massive overproduction of POMC by the anterior pituitary [44]D[89]D. POMC is post-translationally cleaved into ACTH and melanocyte-stimulating hormone (α-MSH) [44]D. High levels of ACTH can also directly bind to the melanocortin-1 receptor (MC1R) on skin melanocytes, stimulating melanin production and causing the characteristic hyperpigmentation of the skin and mucous membranes [44]D.
| Mechanism | Primary Target/Antigen | Key Pathophysiological Feature |
|---|---|---|
| Autoimmune Adrenalitis | 21-hydroxylase (CYP21A2) | CD8+ T-cell mediated destruction; Th1 chemokine (CXCL10) elevation [68][69] |
| X-linked ALD | ABCD1 gene / ALDP protein | Accumulation of VLCFAs causing membrane toxicity in the adrenal cortex [29]D[3]D |
| APS-related PAI | Vascular Endothelium | Adrenal vein thrombosis leading to hemorrhagic infarction [81]C[82]C |
| Mitochondrial PAI | TXNRD2 / Mitochondrial DNA | Oxidative stress and ROS-induced cell death during steroidogenesis [83]C[71] |
| Genetic (FGD) | MC2R / MRAP | Resistance to ACTH signaling despite high circulating ACTH levels [73]D[78]D |
Clinical Features
- ▸Hyperpigmentation in palmar creases and buccal mucosa is the most specific physical sign of primary adrenal insufficiency due to ACTH/MSH receptor cross-reactivity.
- ▸Adrenal crisis should be suspected in any patient with unexplained shock, hyponatremia, and hyperkalemia, especially if preceded by nonspecific fatigue and weight loss.
- ▸Atypical presentations, such as those mimicking eating disorders or lacking hyperpigmentation in specific genetic variants, contribute to significant diagnostic delays.
The clinical presentation of Addison disease, or primary adrenal insufficiency (PAI), is typically insidious, with symptoms progressing over months or years as the adrenal cortex is gradually destroyed [65]D. Because the adrenal glands possess a significant functional reserve, clinical manifestations often remain latent until more than 90% of the cortex is non-functional [48]C. In many cases, the diagnosis is only made when an acute physiological stressor, such as infection or surgery, precipitates an [43]C[70]C.
Presenting Symptoms
Patients initially present with vague, nonspecific symptoms that mimic other systemic illnesses, often leading to diagnostic delays [43]C.
- Fatigue and Asthenia: Persistent, profound fatigue is the most common presenting symptom [65]D. This fatigue is increasingly understood to be linked to the loss of the natural ultradian and circadian rhythms of cortisol secretion, which standard oral replacement therapy fails to replicate [91].
- Distress: , anorexia, and vague abdominal pain are frequent [43]C[65]D. In pediatric populations, vomiting and diarrhea are reported in approximately 48% of cases at onset [103]D.
- Salt Craving: Due to mineralocorticoid deficiency and subsequent urinary sodium wasting, patients often develop a distinct craving for salty foods [65]D.
- Neuropsychiatric Manifestations: Patients may exhibit depression, apathy, or cognitive slowing [65]D. More severe presentations include acute mania or psychosis, which, though rare, are documented complications of the hormonal imbalances in PAI [93].
Physical Examination Findings
A systematic physical examination is essential for identifying the subtle clues of chronic adrenal insufficiency.
- Hyperpigmentation: This is the hallmark of PAI, occurring in over 90% of patients with elevated ACTH [97]C[103]D. It results from the cross-reactivity of high levels of adrenocorticotropic hormone (ACTH) with the melanocortin-1 receptor on melanocytes [14]D[95]C. Hyperpigmentation is most prominent in areas of friction (elbows, knees), palmar creases, recent scars, and the buccal mucosa [65]D[108]C.
- Autonomic and Hemodynamic Signs: Orthostatic hypotension is a key finding, reflecting volume depletion from mineralocorticoid deficiency [49]C[65]D. In advanced stages, persistent hypotension (systolic BP < 100 mmHg) may be present even when supine [49]C.
- Secondary Sexual Characteristics: In women, the loss of adrenal androgens leads to a reduction or loss of axillary and pubic hair [65]D.
- Cardiovascular Progression: Chronic PAI may accelerate the progression of co-existing cardiovascular diseases, such as coronary artery disease, potentially due to chronic inflammatory states and electrolyte imbalances [49]C.
Phenotypic Variants
PAI can present as part of complex genetic syndromes or autoimmune clusters, each with unique clinical features.
| Variant | Key Features | Frequency/Context |
|---|---|---|
| APS Type 2 | Triad of PAI, autoimmune thyroid disease, and Type 1 Diabetes [70]C[96]C. | Most common APS [96]C |
| X-linked AHC | PAI combined with and failure to thrive [103]D. | Pediatric males [103]D |
| FGD | Isolated glucocorticoid deficiency; normal mineralocorticoid function [95]C. | Autosomal recessive [95]C |
| LCAH | Severe steroidogenesis defect; non-classic forms may have complete male genitalia [94]C[105]C. | Rare (StAR mutations) [94]C |
| SPLIS | PAI with steroid-resistant nephrotic syndrome, , and neurological regression [106]C. | SGPL1 variants [106]C |
| PNALD | PAI with global developmental delay, epilepsy, and hearing loss [51]C[62]C. | ACOX1 mutations [62]C |
Red Flags
Clinicians must remain vigilant for signs of impending , a life-threatening emergency. The following findings require immediate intervention:
- Hemodynamic Instability: Refractory shock or severe orthostatic hypotension [48]C.
- Altered Mental Status: Lethargy, confusion, or syncopal episodes [48]C.
- Critical Electrolyte Derangements: Hyponatremia (< 135 mEq/L) and hyperkalemia (> 5.0 mEq/L) [48]C[103]D.
- Hypoglycemia: Particularly common in pediatric patients and those with isolated glucocorticoid deficiency [95]C[103]D.
Atypical Presentations
- PAI Without Hyperpigmentation: While hyperpigmentation is a hallmark, it may be absent in secondary adrenal insufficiency or specific genetic forms of PAI, such as those caused by SPGL1 variants [97]C.
- Eating Disorder Mimicry: The combination of weight loss, anorexia, and vomiting can lead to a misdiagnosis of an eating disorder, particularly in female patients [99]C.
- : Severe B12 deficiency can cause facial and mucosal hyperpigmentation that mimics the "mask" of Addison disease [108]C.
- Medication-Induced: Posaconazole prophylaxis in hematologic patients can disrupt steroidogenesis, leading to an acquired PAI that may be overlooked in the context of complex illness [63]C.
Differential Diagnosis
- ▸Hyperpigmentation and salt craving are unique to primary adrenal insufficiency and do not occur in secondary or tertiary forms.
- ▸Mineralocorticoid deficiency (hypotension, hyperkalemia) is a hallmark of PAI, whereas aldosterone production is typically preserved in SAI/TAI.
- ▸The ACTH stimulation test is the gold standard for diagnosis, but it does not always distinguish between acute SAI and PAI; baseline ACTH levels are required for localization.
The diagnosis of (primary adrenal insufficiency, PAI) is frequently delayed because its initial presentation involves non-specific symptoms such as profound fatigue, weight loss, and anorexia, which overlap with numerous common conditions [120]D[121]D. Clinicians must maintain a high index of suspicion, particularly when these symptoms are accompanied by unexplained hyponatremia or hypotension [125]D[130]D. The primary diagnostic challenge lies in distinguishing PAI from secondary (SAI) or tertiary adrenal insufficiency (TAI), and subsequently ruling out non-endocrine mimics such as occult malignancy, chronic fatigue, or psychiatric disorders [121]D[130]D.
Distinguishing Primary, Secondary, and Tertiary Adrenal Insufficiency
The fundamental distinction between PAI and SAI/TAI is the site of pathology and the specific hormones affected. PAI involves the destruction of the adrenal cortex itself, leading to a deficiency of glucocorticoids, mineralocorticoids, and adrenal androgens [44]D[121]D. In contrast, SAI (pituitary failure) and TAI (hypothalamic failure or exogenous steroid suppression) primarily result in glucocorticoid deficiency [121]D[125]D.
- Hyperpigmentation and Salt Craving: These are hallmark features of PAI. Hyperpigmentation occurs because the lack of cortisol feedback leads to a massive increase in pro-opiomelanocortin (POMC) cleavage, producing both ACTH and melanocyte-stimulating hormone (MSH) [120]D[122]D. Patients with SAI or TAI have low or inappropriately normal ACTH levels and thus do not develop hyperpigmentation [120]D. Salt craving is specific to PAI due to mineralocorticoid (aldosterone) deficiency, which is usually preserved in SAI/TAI because aldosterone production is primarily regulated by the renin-angiotensin-aldosterone system (RAAS) rather than ACTH [125]D.
- Biochemical Differentiation: In PAI, low morning cortisol is paired with significantly elevated ACTH (often >2 times the upper limit of normal) and elevated plasma renin activity [125]D[127]D. In SAI/TAI, ACTH is low or inappropriately normal, and renin levels remain stable [121]D.
- Etiological Clues: PAI is most commonly autoimmune in adults (associated with other ) or infectious (e.g., tuberculosis) [44]D[121]D. SAI is often caused by pituitary tumors, surgery, or cranial radiation [77]D[121]D. TAI is most frequently the result of abrupt cessation of long-term exogenous glucocorticoid therapy [44]D[121]D.
Clinical Mimics and Non-Endocrine Disorders
Because the symptoms of adrenal insufficiency are "great mimickers," several systemic conditions must be excluded [130]D.
- and Malignant Disorders: , anorexia, and abdominal pain may suggest occult malignancy or malabsorption syndromes [120]D[121]D. However, the presence of hyperkalemia and hyponatremia strongly points toward PAI rather than simple malnutrition [120]D.
- Psychiatric and Functional Disorders: and major depressive disorder share the lethargy and malaise seen in AI [120]D. may mimic the weight loss and hypotension of AI, but the biochemical profile of cortisol and ACTH will differ; patients with anorexia nervosa may actually have elevated cortisol due to stress, whereas AI patients will have profound deficiency [121]D.
- Liver Disease: Patients with cirrhosis often have reduced levels of cortisol-binding globulin and altered cortisol clearance, which can complicate the interpretation of total serum cortisol levels [132]D.
- Pregnancy: The physiological hypercortisolemia of pregnancy can mask AI, while the common symptoms of pregnancy (nausea, vomiting, fatigue) overlap with early adrenal crisis [118]D. Diagnosis in pregnancy requires higher cortisol thresholds for stimulation tests due to increased cortisol-binding globulin [118]D.
Iatrogenic and Emerging Differentials
- Immune Checkpoint Inhibitors (ICIs): Modern oncology treatments (e.g., PD-1 or CTLA-4 inhibitors) can induce various endocrine immune-related adverse events (irAEs) [112][119]D. While ICIs more commonly cause (leading to SAI), they can rarely cause direct autoimmune adrenalitis (PAI) [114][124][127]D. Distinguishing these is critical as SAI from hypophysitis may be associated with other pituitary hormone deficiencies [112][119]D.
- Envenoming: In certain geographic regions, snakebites (particularly from vipers) can cause acute or chronic , presenting as SAI years after the initial event [126]D.
Diagnostic Algorithm for Differentiation
Step 1: Confirm Hypocortisolism. Measure 8 AM serum cortisol. If <140 nmol/L (5 mcg/dL), AI is highly likely [125]D. Step 2: Locate the Defect. Measure plasma ACTH. High ACTH indicates PAI; low/normal ACTH indicates SAI or TAI [125]D[127]D. Step 3: Assess Mineralocorticoid Status. In suspected PAI, measure plasma renin and aldosterone. Elevated renin with low aldosterone confirms PAI [125]D. Step 4: Provocative Testing. If baseline tests are inconclusive, perform a standard ACTH stimulation test (250 mcg). A peak cortisol <500 nmol/L (18 mcg/dL) at 30 or 60 minutes confirms AI [110][125]D. Step 5: Identify Etiology. For PAI, order 21-hydroxylase antibodies or adrenal imaging [127]D. For SAI/TAI, order pituitary MRI [121]D.
| Feature | Primary (PAI) | Secondary (SAI) | Tertiary (TAI) |
|---|---|---|---|
| Primary Site | Adrenal Cortex | Anterior Pituitary | Hypothalamus |
| Cortisol | Low | Low | Low |
| ACTH | High | Low / Normal | Low / Normal |
| Aldosterone | Low | Normal | Normal |
| Renin | High | Normal | Normal |
| Skin Color | Hyperpigmentation | Pallor | Pallor |
| Common Cause | Autoimmune, Infection | Pituitary Tumor | Exogenous Steroids |
| Symptom Cluster | Differential Diagnoses | Differentiating Findings |
|---|---|---|
| Fatigue & Weight Loss | Malignancy, Depression, Chronic Fatigue | AI has specific electrolyte gaps (Low Na, High K) [120]D[121]D |
| Nausea & Vomiting | Pregnancy, Gastroenteritis | AI presents with postural hypotension and salt craving [118]D[130]D |
| Hyponatremia | SIADH, Cirrhosis, Heart Failure | AI hyponatremia is often associated with hyperkalemia and high renin [125]D[132]D |
| Acute Hypotension | Sepsis, Cardiogenic Shock | Adrenal crisis is refractory to vasopressors but responds to fluids and glucocorticoids [130]D |
Prognosis and Long-term Outcomes
- ▸Mortality in primary adrenal insufficiency remains significantly higher than the general population, primarily due to cardiovascular disease, infections, and adrenal crises.
- ▸Quality of life is chronically impaired, with fatigue being the most common persistent symptom, particularly in women.
- ▸Pregnancy in PAI carries a high risk of adrenal crisis (18.8%), requiring intensive multidisciplinary monitoring.
The prognosis for patients with primary adrenal insufficiency (PAI), or , has historically been considered excellent with lifelong hormone replacement. However, contemporary evidence indicates that despite standard therapy, patients face increased mortality, reduced quality of life (QoL), and significant long-term morbidity [137][142]D. The primary challenges in long-term stem from the inability of current oral replacement regimens to replicate the complex circadian and ultradian rhythms of endogenous cortisol secretion [91][142]D.
Mortality and Life Expectancy
Recent systematic reviews and meta-analyses confirm that mortality remains unacceptably high in the PAI population [137][142]D. While specific rates vary by etiology, the overall mortality risk is significantly elevated compared to the general population, with standardized mortality ratios often exceeding 2.0 [137]. The leading causes of death include cardiovascular disease, infectious complications, and acute adrenal crisis [137][151]D.
In specific subtypes, such as adrenal , mortality can be as high as 18-20% if diagnosis is delayed [138]. In patients with antiphospholipid syndrome-associated adrenal hemorrhage (APS-AH), the mortality rate is approximately 10% [1]. Conversely, in immune checkpoint inhibitor (ICI)-induced PAI, the development of endocrine adverse events may paradoxically correlate with a more favorable oncological prognosis, provided the adrenal insufficiency is managed appropriately [149]D.
Quality of Life and Functional Status
Patients with PAI frequently report a diminished subjective health status [145]D. This is often quantified using the AddiQoL (Quality of Life in Addison's Disease) questionnaire, where lower scores indicate greater impairment [150]D.
- Gender Differences: Males typically report significantly higher AddiQoL scores than females, particularly in domains related to fatigue and emotional stability [150]D.
- Fatigue and Mood: Chronic fatigue remains the most persistent symptom, affecting daily functioning and emotional well-being [143]D[150]D. This is partly attributed to the "peaks and troughs" of conventional hydrocortisone (e.g., 20 mg/day divided into 2-3 doses), which fail to maintain stable nocturnal and early-morning cortisol levels [143]D.
- Socioeconomic Impact: PAI is associated with significant work loss and reduced taxable earnings [147]D. Patients often experience a decline in disposable income and may require more frequent sick leave compared to healthy peers [147]D.
Long-term Sequelae and Comorbidities
Chronic glucocorticoid replacement, even at "physiologic" doses, can lead to multi-system complications over decades of therapy.
Bone Health and Osteoporosis
Conventional glucocorticoid replacement is associated with a detrimental effect on skeletal health, leading to an increased risk of fractures [152]D. This occurs because standard oral doses often result in supraphysiological peaks that inhibit osteoblast activity and stimulate bone resorption. Recent data suggest that dual-release hydrocortisone (DR-HC) may offer a more favorable bone safety profile than conventional formulations, as it better mimics the natural cortisol decline throughout the day [152]D.
Cardiovascular and Metabolic Risks
Patients with PAI exhibit altered biomarkers of cardiovascular inflammation [30]D. There is an increased prevalence of metabolic syndrome and cardiovascular disease, likely driven by the lack of nocturnal cortisol dip and the metabolic consequences of intermittent over-replacement [30]D[142]D. Furthermore, patients are at a heightened risk for hypoglycemia, particularly during periods of prolonged fasting such as Ramadan, where continuous glucose monitoring has shown significant glucose fluctuations despite stable medication doses [16].
Reproductive Outcomes
In women, autoimmune PAI is frequently associated with premature ovarian insufficiency (POI), occurring in 6-10% of cases [25]D. This significantly impacts fertility and may precede the adrenal diagnosis [25]D. For those who achieve pregnancy, the risk of an adrenal crisis is approximately 18.8%, with the highest risk occurring in the first trimester and the immediate postpartum period [134]. Systematic reviews indicate an increased prevalence of preterm birth and small-for-gestational-age (SGA) neonates in mothers with PAI [17].
Emerging Prognostic Improvements
Advancements in delivery technology are showing promise in improving long-term outcomes. Continuous subcutaneous hydrocortisone infusion (CSHI), or pump therapy, can more closely mimic the physiological ultradian rhythm [91][136]. In pediatric populations, CSHI has been shown to improve growth velocity and disease control in cases where oral therapy failed [136][144]D. Similarly, the use of dehydroepiandrosterone (DHEA) (e.g., 25-50 mg daily) in women may improve mood and libido, though its long-term impact on overall mortality is not yet established [117]C.
Long-term Monitoring Protocol
To optimize prognosis, clinicians should follow a structured longitudinal assessment:
- Annual Clinical Review: Assess for symptoms of over-replacement (weight gain, striae) or under-replacement (fatigue, hyperpigmentation) [142]D[146]D.
- Biometric Screening: Monitor blood pressure, BMI, and HbA1c annually to manage cardiovascular and metabolic risks [30]D[142]D.
- Bone Density: Perform DXA scans every 3-5 years, especially in postmenopausal women or those on higher glucocorticoid doses [152]D.
- Crisis Prevention Education: Re-verify the patient's possession of an emergency injection kit and their understanding of "sick day rules" at every visit [134][142]D.
| Factor | Favorable Prognosis | Poor Prognosis |
|---|---|---|
| Etiology | Immune checkpoint inhibitor-induced (better cancer survival) [149]D | Adrenal Histoplasmosis or Malignancy [138][140]C |
| Delivery Method | Pulsatile pump or Dual-release formulations [91][152]D | Conventional oral hydrocortisone (multiple daily peaks) [142]D |
| Adherence | High adherence to sick day rules and emergency kit use [134] | Frequent missed doses or lack of emergency education [142]D |
| Comorbidities | Isolated PAI | Presence of POI or APS [1][25]D |
| Monitoring | Regular AddiQoL assessment and biometric screening [150]D | Infrequent follow-up or unmonitored replacement [144]D |
Special Populations
- ▸Pregnancy requires a 20–50% increase in hydrocortisone during the third trimester and high-dose IV supplementation (100 mg) during active labor to prevent crisis.
- ▸Hydrocortisone is the preferred treatment in pediatrics at 8–12 mg/m²/day to minimize growth suppression associated with longer-acting glucocorticoids.
- ▸Patients with comorbid diabetes mellitus and Addison disease face a significantly higher mortality risk and require vigilant monitoring for hypoglycemia.
The of (primary adrenal insufficiency, PAI) requires significant modification across different life stages and clinical scenarios. Physiological changes in pregnancy, developmental requirements in children, and the metabolic demands of surgery necessitate precise adjustments to glucocorticoid and mineralocorticoid replacement to prevent and long-term morbidity [118]D[153].
Pregnancy and Reproductive Health
Pregnancy is a state of physiological hypercortisolemia, driven by placental production of corticotropin-releasing hormone (CRH) and increased levels of cortisol-binding globulin (CBG) [118]D[168]D. Diagnosis is often delayed because symptoms of PAI—such as nausea, vomiting, and fatigue—overlap with normal pregnancy [118]D[164]C. However, untreated PAI carries severe risks, including a 3.9-fold increase in spontaneous abortion and higher rates of preterm birth and small-for-gestational-age (SGA) neonates [17][156].
Management Protocol for Pregnancy:
- Step 1 (First/Second Trimester): Maintain standard replacement doses (typically hydrocortisone 15–25 mg/day in divided doses). Monitor for hyperemesis gravidarum, which may necessitate parenteral hydrocortisone to prevent crisis [118]D[153].
- Step 2 (Third Trimester): Increase the hydrocortisone dose by 20–50% (approximately 5–10 mg/day extra) to account for increased CBG and physiological demand [153][162]D.
- Step 3 (Labor and Delivery): At the onset of active labor, administer hydrocortisone 100 mg IV, followed by an infusion of 200 mg/24 hours or 50 mg IV every 6 hours [153][118]D.
- Step 4 (Postpartum): Rapidly taper to pre-pregnancy maintenance doses over 48–72 hours following delivery [153].
Mineralocorticoid requirements (fludrocortisone) generally remain stable, though doses may need adjustment if significant salt-wasting occurs or if progesterone's anti-mineralocorticoid effects become dominant [118]D[153]. is considered safe with standard replacement doses, as the amount of glucocorticoid excreted in breast milk is negligible [153].
Pediatrics
In the pediatric population, the etiology of PAI differs significantly from adults. While autoimmune adrenalitis is the leading cause in adults, (CAH) and X-linked (ALD) are more prevalent in children [47]D[61]D. ALD affects over 80% of affected males and requires lifelong surveillance [160]D. Rare syndromes like Sphingosine Lyase Insufficiency Syndrome (SPLIS) present with steroid-resistant nephrotic syndrome and PAI in early childhood [169]C.
Clinical Considerations:
- Growth Monitoring: Hydrocortisone is the preferred glucocorticoid in children (standard dose 8–12 mg/m²/day) because longer-acting steroids like dexamethasone are associated with significant growth suppression and stunting [153][161]D.
- Puberty: In girls with autoimmune PAI, there is a 10–20% risk of developing (POI) [25]D[166]D. The presence of steroid-cell autoantibodies (StCA) is highly predictive of future POI [166]D.
- Developmental Impact: Children with ALD require regular brain MRI monitoring to detect early cerebral involvement, which may necessitate hematopoietic stem cell transplantation [61]D[160]D.
Elderly and Comorbidities
Elderly patients often have multiple comorbidities that complicate PAI management. A critical interaction exists between PAI and . Patients with both conditions have a significantly higher mortality risk compared to those with diabetes alone [157].
Management Modifications:
- Diabetes: Glucocorticoid replacement can worsen glycemic control. Conversely, an adrenal crisis may present as unexplained, recurrent hypoglycemia [157][162]D.
- Cardiovascular Disease: Excessive mineralocorticoid replacement in the elderly can exacerbate and heart failure. Fludrocortisone doses should be carefully titrated to the lowest effective dose that maintains normal electrolytes and blood pressure [153].
Perioperative Management
Patients with PAI cannot mount a physiological cortisol response to surgical stress, placing them at high risk for perioperative adrenal crisis [109][171]D. The degree of supplementation depends on the severity of the surgical stress.
Stress Dosing Protocol:
- Minor Surgery/Procedures (e.g., local anesthesia): Usually requires only the standard morning dose. Recent trials suggest routine supplementation may not be necessary for minor dental work under local anesthesia [154].
- Moderate Stress (e.g., ): Administer hydrocortisone 50–75 mg IV on the day of surgery, tapering to maintenance over 24 hours [109].
- Major Surgery (e.g., cardiothoracic, major abdominal): Administer hydrocortisone 100 mg IV at induction, followed by 200 mg/24 hours via continuous infusion or 50 mg IV every 6 hours for 48–72 hours [109][153].
| Procedure Type | Hydrocortisone Dose | Duration |
|---|---|---|
| Minor (e.g., dental, skin biopsy) | Standard daily dose | No extra dose needed [154] |
| Moderate (e.g., joint replacement) | 50–75 mg IV/IM | Taper to maintenance in 24h [109] |
| Major (e.g., open abdominal) | 100 mg IV bolus, then 200 mg/24h | Taper over 48–72h [153] |
| Critical Care/Sepsis | 100 mg IV bolus, then 200 mg/24h | Until clinical stability [109] |
Prevention and Screening
- ▸First-degree relatives of patients with Addison disease have a **38.1%** risk of developing an autoimmune disorder, necessitating low-threshold screening for endocrine autoantibodies [186].
- ▸Adrenal insufficiency affects **over 80%** of males with X-linked adrenoleukodystrophy; newborn screening and lifelong adrenal surveillance are mandatory to prevent crisis [160, 61].
- ▸Immune checkpoint inhibitor (ICI) therapy carries a **1-5%** risk of inducing primary adrenal insufficiency, which often presents with non-specific symptoms like fatigue and hyponatremia [178, 191].
Prevention of and its life-threatening complication, the adrenal crisis, relies on the early identification of high-risk individuals and the implementation of rigorous surveillance protocols for those exposed to predisposing factors. While primary prevention of autoimmune or genetic adrenal destruction is currently not possible, secondary prevention through screening and patient education is essential to reduce morbidity and mortality [175][178]D.
Screening in High-Risk Populations
Individuals with existing autoimmune conditions or a family history of endocrine disorders are at the highest risk for developing autoimmune primary adrenal insufficiency (PAI). Autoimmune conditions tend to cluster; for instance, 38.1% of first-degree relatives of patients with Addison disease are diagnosed with at least one autoimmune condition [186]D. In these relatives, Hashimoto's thyroiditis is found in 20.3%, Graves' disease in 8.0%, and Addison disease itself in 2.7% [186]D.
Screening for organ-specific autoantibodies (e.g., 21-hydroxylase antibodies) is recommended in patients with (PAS) types II and III, as these syndromes involve a high prevalence of associated disorders affecting both endocrine and non-endocrine organs [176]. In patients with suspected monogenic immune deficiencies like (APS-1), screening for cytokine autoantibodies, specifically anti-interferon-omega (IFN-ω) and anti-interleukin-22 (IL-22), serves as a highly sensitive diagnostic marker [185]D. APECED is characterized by a classic triad of , , and PAI, often preceded by fungal nail infections in early childhood [183]C[184]D[187]C.
Genetic Screening and Newborn Programs
Early detection of genetic causes of PAI is critical to prevent sudden death from salt-wasting crises or irreversible neurological damage.
- (CAH): Newborn screening (NBS) for 21-hydroxylase deficiency is standard in many regions to identify infants before they develop life-threatening hyponatremia and hyperkalemia [188]C[189]C. Rare forms, such as 3β-hydroxysteroid dehydrogenase type 2 deficiency, may also be detected through these programs [188]C.
- X-linked Adrenoleukodystrophy (X-ALD): This progressive disorder affects the adrenal cortex and nervous system due to mutations in the ABCD1 gene [29]D[160]D. Adrenal insufficiency affects over 80% of male ALD patients [160]D. Because PAI often develops before neurological symptoms, NBS and subsequent longitudinal monitoring are vital [45]D[61]D.
- Rare Syndromes: Screening should be considered in pediatric patients presenting with non-specific symptoms like failure to thrive or seizures, which may indicate rare genetic etiologies like Sphingosine-1-phosphate lyase (SGPL1) insufficiency or Triple A (Allgrove) syndrome [180]D[181]C[182]C.
Monitoring Drug-Induced Adrenal Insufficiency
The emergence of modern antineoplastic therapies has introduced new risks for PAI. Clinicians must maintain a high index of suspicion for patients on the following regimens:
- Immune Checkpoint Inhibitors (ICIs): Drugs targeting CTLA-4, PD-1, or PD-L1 can trigger autoimmune adrenalitis [175][179]D. PAI occurs in 1-2% of patients on single ICI therapy and increases to approximately 5% with combination therapy [178]D.
- Tyrosine Kinase Inhibitors (TKIs): Agents such as cabozantinib and lenvatinib have been associated with primary adrenal dysfunction [177][42]D. In patients treated with lenvatinib, fatigue is a common adverse event that may actually stem from underlying cortisol deficiency [42]D.
Protocol: Surveillance for Patients on Immunotherapy
To prevent lethal adrenal crises in cancer patients, the following monitoring protocol is recommended [178]D[179]D[191]C:
- Step 1: Obtain baseline morning cortisol and ACTH levels before initiating ICI or TKI therapy.
- Step 2: Perform periodic biochemical monitoring (electrolytes and cortisol) during treatment, especially if the patient reports non-specific symptoms like fatigue, anorexia, or nausea.
- Step 3: If hyponatremia or hypotension develops, immediately evaluate for PAI to distinguish it from other causes like the syndrome of inappropriate antidiuresis (SIAD) [191]C.
Prevention of Adrenal Crisis
Secondary prevention focuses on preventing the progression of PAI to an adrenal crisis. This is achieved through:
- Early Recognition: Identifying subtle signs such as hyperpigmentation, salt craving, or unexplained fatigue [178]D[182]C.
- Infection : Infections are a major trigger for crisis. Patients with PAI, particularly those with underlying immunodeficiencies like APECED, require prompt treatment of infections and may need "sick day" dose adjustments (though specific dosing is handled in Management) [180]D[184]D[185]D.
- Vigilance in Endemic Areas: In certain regions, screening for infectious causes like adrenal tuberculosis is necessary, as it remains a significant cause of PAI [50]C.
| High-Risk Group | Estimated Prevalence of PAI | Screening Recommendation |
|---|---|---|
| X-linked Adrenoleukodystrophy (Males) | >80% [160]D | Newborn screening; regular ACTH/cortisol monitoring [61]D |
| Combination ICI Therapy | ~5% [178]D | Baseline and periodic cortisol/ACTH during treatment [179]D |
| Single ICI Therapy | 1-2% [178]D | Clinical vigilance for fatigue and hyponatremia [191]C |
| APECED (APS-1) | High (part of classic triad) [184]D | Anti-IFN-ω and anti-IL-22 autoantibodies [185]D |
| First-degree relatives of AD patients | 2.7% [186]D | 21-hydroxylase antibody testing if symptomatic [186]D |
References
- [1]
Meade-Aguilar JA, Figueroa-Parra G, Yang JX et al.. “Clinical presentation and outcomes in patients with antiphospholipid syndrome-associated adrenal hemorrhage. A multicenter cohort study and systematic literature review.” Clinical immunology (Orlando, Fla.) (2024). PMID: 38244823 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [2]
Phadte A, Dhole C, Hegishte S et al.. “Steroidogenic acute regulatory protein (STAR) deficiency: Our experience and systematic review for phenotype-genotype correlation.” Clinical endocrinology (2024). PMID: 38368602 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Engelen M, Kemp S, Poll-The BT. “X-linked adrenoleukodystrophy: pathogenesis and treatment.” Current neurology and neuroscience reports (2014). PMID: 25115486 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Pathophysiology - [4]
Brandão Neto RA, de Carvalho JF. “Diagnosis and classification of Addison's disease (autoimmune adrenalitis).” Autoimmunity reviews (2014). PMID: 24424183 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [5]
Mytareli C, Ziogas DC, Karampela A et al.. “The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.” Cancers (2023). PMID: 37046677 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors, Pathophysiology - [6]
Wang QH, Wang YY, Wang J et al.. “Easily misdiagnosed X-linked adrenoleukodystrophy.” Italian journal of pediatrics (2024). PMID: 38956688 ↗
L4CASE_REPORTCited in: Definition, Synonyms, and Classification, Epidemiology and Risk Factors, Etiology and Triggering Factors - [7]
Weismann D. “[Endocrine emergencies].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2026). PMID: 41805972 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [8]
Gatti R, Antonelli G, Prearo M et al.. “Cortisol assays and diagnostic laboratory procedures in human biological fluids.” Clinical biochemistry (2009). PMID: 19414006 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [9]
Rushworth RL, Torpy DJ, Stratakis CA et al.. “Adrenal Crises in Children: Perspectives and Research Directions.” Hormone research in paediatrics (2018). PMID: 29874655 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [10]
Olafsson AS, Sigurjonsdottir HA. “INCREASING PREVALENCE OF ADDISON DISEASE: RESULTS FROM A NATIONWIDE STUDY.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2016). PMID: 26437215 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [11]
Rios-Duarte JA, Sanchez-Zapata MJ, Silverberg JI. “Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study.” Archives of dermatological research (2023). PMID: 37405428 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [12]
Bernard F, Outtrim J, Menon DK et al.. “Incidence of adrenal insufficiency after severe traumatic brain injury varies according to definition used: clinical implications.” British journal of anaesthesia (2006). PMID: 16311283 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [13]
Farrugia FA, Martikos G, Surgeon C et al.. “Radiology of the adrenal incidentalomas. Review of the literature.” Endocrine regulations (2017). PMID: 28222025 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Barros-Oliveira CS, Oliveira CRP, Silva BS et al.. “Clinical dermatoendocrinology: saving lives by looking at the skin.” Archives of endocrinology and metabolism (2025). PMID: 41313191 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification, History and Physical Examination - [15]
Shepherd LM, Schmidtke KA, Hazlehurst JM et al.. “Interventions for the prevention of adrenal crisis in adults with primary adrenal insufficiency: a systematic review.” European journal of endocrinology (2022). PMID: 35536876 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors - [16]
Chihaoui M, Sta J, Kamoun E et al.. “Hypoglycaemia and other risks of ramadan fasting in patients with primary adrenal insufficiency: A prospective controlled trial using 24-hour glucose monitoring.” Journal of endocrinological investigation (2026). PMID: 41108503 ↗
L1bRCTCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [17]
Ilia G, Paltoglou G, Chatzakis C et al.. “Increased prevalence of negative pregnancy and fetal outcomes in women with primary adrenal insufficiency. A systematic review and meta-analysis.” Endocrine (2024). PMID: 39277840 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Special Populations - [18]
Stergianos S, Spelman T, Eriksson D et al.. “Increased risk of osteoporotic fractures and osteoporosis in patients with Addison's disease in Sweden: A nationwide population-based cohort study.” Journal of internal medicine (2025). PMID: 40190018 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [19]
Öster S, Esposito D, Aranda-Guillén M et al.. “Self-management and hospitalization in 615 Swedish patients with Addison's disease during the coronavirus disease 2019 pandemic: a retrospective study.” European journal of endocrinology (2023). PMID: 36721983 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors - [20]
Labadzhyan A, Wentzel K, Hamid O et al.. “Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35303106 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Pathophysiology - [21]
Treeful AE, Searle KM, Carroll DM et al.. “A case-control survey study of environmental risk factors for primary hypoadrenocorticism in dogs.” Journal of veterinary internal medicine (2023). PMID: 37830238 ↗
L3bCASE_CONTROLCited in: Epidemiology and Risk Factors - [22]
Coniac S, Costache Outas MC, Pirvu EE et al.. “Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy-Retrospective Study from a Tertiary-Level Hospital in Romania.” Diagnostics (Basel, Switzerland) (2023). PMID: 37238273 ↗
L2bCOHORTCited in: Epidemiology and Risk Factors, Prevention and Screening - [23]
Honda M, Narumi S, Hasegawa K et al.. “Coproporphyrinogen Oxidase Deficiency Causes Primary Adrenal Insufficiency and 46,XY DSD.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40481674 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [24]
Monti S, Fazzalari B, Renzelli V et al.. “Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency.” Frontiers in endocrinology (2025). PMID: 41561040 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [25]
O'Murchadha L, Pazderska A. “Female fertility and pregnancy in autoimmune Addison's disease - a mini review.” Frontiers in endocrinology (2025). PMID: 40607215 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes, Special Populations - [26]
Musa SA, Abdullah MA, Hassan SS et al.. “Novel recurrent mutations and genetic diversity in Sudanese children with adrenal insufficiency.” European journal of endocrinology (2025). PMID: 40063902 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [27]
Shao W, Yang K, Lu D et al.. “Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39986331 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [28]
Hamidi O, Miljanic M, Tumyan G et al.. “Adrenal Insufficiency following Stereotactic Ablative Radiotherapy (SAbR) of Adrenal Gland Metastases.” Cancers (2024). PMID: 39335112 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [29]
Cappa M, Todisco T, Bizzarri C. “X-linked adrenoleukodystrophy and primary adrenal insufficiency.” Frontiers in endocrinology (2023). PMID: 38034003 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Etiology and Triggering Factors, Pathophysiology, Prevention and Screening - [30]
Sævik ÅB, Ueland G, Åkerman AK et al.. “Altered biomarkers for cardiovascular disease and inflammation in autoimmune Addison's disease - a cross-sectional study.” European journal of endocrinology (2023). PMID: 37807083 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prognosis and Long-term Outcomes - [31]
Naessén S, Eliasson M, Berntorp K et al.. “Autoimmune Disease in Turner Syndrome in Sweden: An up to 25 Years' Controlled Follow-up Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37758506 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [32]
Harasymiw LA, Grosse SD, Cullen KR et al.. “Depressive and anxiety disorders and antidepressant prescriptions among insured children and young adults with congenital adrenal hyperplasia in the United States.” Frontiers in endocrinology (2023). PMID: 37664854 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [33]
Lundtoft C, Eriksson D, Bianchi M et al.. “Relation between HLA and copy number variation of steroid 21-hydroxylase in a Swedish cohort of patients with autoimmune Addison's disease.” European journal of endocrinology (2023). PMID: 37553728 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [34]
Borchers J, Pukkala E, Mäkitie O et al.. “Epidemiology and Causes of Primary Adrenal Insufficiency in Children: A Population-Based Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37216903 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology and Triggering Factors - [35]
Aranda-Guillén M, Røyrvik EC, Fletcher-Sandersjöö S et al.. “A polygenic risk score to help discriminate primary adrenal insufficiency of different etiologies.” Journal of internal medicine (2023). PMID: 37151110 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [36]
Lu D, Yao J, Yuan G et al.. “Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS.” Journal of endocrinological investigation (2022). PMID: 35870109 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [37]
Borchers J, Mäkitie O, Jääskeläinen J et al.. “Recurrent Hypokalemia and Adrenal Steroids in Patients With APECED.” Frontiers in endocrinology (2022). PMID: 35813662 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [38]
Røyrvik EC, Husebye ES. “The genetics of autoimmune Addison disease: past, present and future.” Nature reviews. Endocrinology (2022). PMID: 35411072 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [39]
Kim MS, Fraga NR, Minaeian N et al.. “Components of Metabolic Syndrome in Youth With Classical Congenital Adrenal Hyperplasia.” Frontiers in endocrinology (2022). PMID: 35399922 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Pathophysiology - [40]
Schonfeld SJ, Tucker MA, Engels EA et al.. “Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.” JAMA network open (2022). PMID: 35315916 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis - [41]
Meling Stokland AE, Ueland G, Lima K et al.. “Autoimmune Thyroid Disorders in Autoimmune Addison Disease.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35226748 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [42]
Monti S, Presciuttini F, Deiana MG et al.. “Cortisol Deficiency in Lenvatinib Treatment of Thyroid Cancer: An Underestimated Common Adverse Event.” Thyroid : official journal of the American Thyroid Association (2022). PMID: 34663079 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Prevention and Screening - [43]
Zhai H, Zou S, Tan Y et al.. “Primary adrenocortical insufficiency in patients with AIDS in Wuhan, China: 3 cases report and literature review.” BMC infectious diseases (2025). PMID: 41316044 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination - [44]
Vaidya A, Findling J, Bancos I. “Adrenal Insufficiency in Adults: A Review.” JAMA (2025). PMID: 40522647 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Pathophysiology, Differential Diagnosis - [45]
Kornbluh AB, Baldwin A, Fatemi A et al.. “Practical Approach to Longitudinal Neurologic Care of Adults With X-Linked Adrenoleukodystrophy and Adrenomyeloneuropathy.” Neurology. Genetics (2024). PMID: 39372123 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes, Prevention and Screening - [46]
Hasenmajer V, Ferrigno R, Minnetti M et al.. “Rare forms of genetic paediatric adrenal insufficiency: Excluding congenital adrenal hyperplasia.” Reviews in endocrine & metabolic disorders (2023). PMID: 36763264 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Differential Diagnosis, Prevention and Screening - [47]
Graves LE, Torpy DJ, Coates PT et al.. “Future Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36611246 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes, Special Populations - [48]
Bouki K, Venetsanaki V, Chrysoulaki M et al.. “Primary adrenal insufficiency due to bilateral adrenal hemorrhage-adrenal infarction in a patient with systemic lupus erythematosus and antiphospholipid syndrome: case presentation and review of the literature.” Hormones (Athens, Greece) (2023). PMID: 37436639 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination - [49]
Zhao R, Luo S, Wang S et al.. “Coronary artery disease in a patient with Addison's disease: a case report and literature review.” BMC cardiovascular disorders (2023). PMID: 36709280 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination - [50]
Xiong T, Wang R, Zhou J et al.. “Case Report: Adrenal tuberculosis causing primary adrenal insufficiency: diagnosis by ultrasound-guided biopsy.” Frontiers in medicine (2025). PMID: 41357490 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Prevention and Screening - [51]
Helvacioglu D, Canbaz AT, Tekmenuray-Unal A et al.. “Primary adrenal insufficiency caused by pseudo-neonatal adrenoleukodystrophy associated with biallelic ACOX1 mutations.” European journal of endocrinology (2025). PMID: 40326779 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination - [52]
Fischetti G, Barbone A, Giovannico L et al.. “Case Report: Primary adrenal insufficiency due to bilateral adrenal infarction and antiphospholipid syndrome in Covid19 - A complicate case of cardiogenic shock.” Frontiers in endocrinology (2025). PMID: 40241990 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [53]
Arrigoni M, Cavarzere P, Nicolussi Principe L et al.. “Autoimmune adrenal insufficiency in children: a hint for polyglandular syndrome type 2?” Italian journal of pediatrics (2023). PMID: 37516895 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [54]
Kaneto H, Tatsumi F, Ohnishi M et al.. “Addison's disease triggered by infection with mycobacterium abscessus, but not by adrenal tuberculosis or MAC pulmonary disease, in a subject with type 2 diabetes mellitus: case report.” BMC endocrine disorders (2022). PMID: 36274124 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [55]
Lindh JD, Patrova J, Rushworth RL et al.. “Tuberculosis of Adrenal Glands-A Population-based Case-control Study.” Journal of the Endocrine Society (2023). PMID: 37122590 ↗
L3bCASE_CONTROLCited in: Etiology and Triggering Factors, Prognosis and Long-term Outcomes - [56]
Rushworth RL, Chrisp GL, Bownes S et al.. “Adrenal crises in adolescents and young adults.” Endocrine (2022). PMID: 35583847 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [57]
Jiang W, Chen D, Yang D et al.. “Adrenal Hemorrhage in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Case Report and Literature Review.” International journal of endocrinology (2023). PMID: 37794979 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, Prevention and Screening - [58]
Zekarias KL, Salim M, Tessier KM et al.. “Adrenal insufficiency and the use of mineralocorticoid treatment in male patients with adrenoleukodystrophy; a retrospective analysis of an institutional database.” BMC endocrine disorders (2024). PMID: 39252037 ↗
L5OTHERCited in: Etiology and Triggering Factors - [59]
Dogra P, Chinthapalli M, Sandooja R et al.. “Adrenal Hemorrhage: A Comprehensive Analysis of a Heterogeneous Entity-Etiology, Presentation, Management, and Outcomes.” Mayo Clinic proceedings (2024). PMID: 38432745 ↗
L5OTHERCited in: Etiology and Triggering Factors - [60]
Dohr KA, Tokic S, Gastager-Ehgartner M et al.. “Two Single Nucleotide Deletions in the ABCD1 Gene Causing Distinct Phenotypes of X-Linked Adrenoleukodystrophy.” International journal of molecular sciences (2023). PMID: 36983033 ↗
L5OTHERCited in: Etiology and Triggering Factors - [61]
Engelen M, van Ballegoij WJC, Mallack EJ et al.. “International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach.” Neurology (2022). PMID: 36175155 ↗
L5OTHERCited in: Etiology and Triggering Factors, Special Populations, Prevention and Screening - [62]
Turan İ, Bulut FD, Kotan LD et al.. “Primary Adrenal Insufficiency in Pseudo-Neonatal Adrenoleukodystrophy Case Report.” Journal of clinical research in pediatric endocrinology (2026). PMID: 41797577 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination, Prevention and Screening - [63]
Precali A, Roncevic P, Kraljevic I. “Posaconazole-induced primary adrenal insufficiency: A rare but real risk.” Annales d'endocrinologie (2024). PMID: 38242202 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors, History and Physical Examination - [64]
Wiersma RE, Gupta AO, Lund TC et al.. “Primary Adrenal Insufficiency in a Boy with Type I Diabetes: The Importance of Considering X-linked Adrenoleukodystrophy.” Journal of the Endocrine Society (2022). PMID: 35450414 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [65]
Agius M, Agius M. “A DESCRIPTION OF ADDISON'S DISEASE, AND ITS NEUROPSYCHIATRIC MANIFESTATIONS COMPARING THE DISEASE AS IT IS NOW TO THE DISEASE AS EXPERIENCED BY SAINT ELIZABETH OF THE TRINITY IN 1906.” Psychiatria Danubina (2025). PMID: 40982814 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, History and Physical Examination - [66]
Popescu M, Terzea DC, Carsote M et al.. “COVID-19 infection: from stress-related cortisol levels to adrenal glands infarction.” Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (2022). PMID: 36074666 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors - [67]
Melvin A, Chantzichristos D, Kyle CJ et al.. “GDF15 Is Elevated in Conditions of Glucocorticoid Deficiency and Is Modulated by Glucocorticoid Replacement.” The Journal of clinical endocrinology and metabolism (2020). PMID: 31853550 ↗
L1bRCTCited in: Pathophysiology - [68]
Dawoodji A, Chen JL, Shepherd D et al.. “High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients.” Journal of immunology (Baltimore, Md. : 1950) (2014). PMID: 25063864 ↗
L2bTRIAL_NONRANDOMCited in: Pathophysiology - [69]
Ekman B, Alstrand N, Bachrach-Lindström M et al.. “Altered chemokine Th1/Th2 balance in Addison's disease: relationship with hydrocortisone dosing and quality of life.” Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2014). PMID: 23918683 ↗
L1bRCTCited in: Pathophysiology - [70]
Yao Z, Chen H, Hu X et al.. “Delayed diagnosis of the full triad autoimmune polyendocrine syndrome type 2 with adrenal crisis: a case report and literature review.” Frontiers in immunology (2025). PMID: 40416965 ↗
L4CASE_REPORTCited in: Pathophysiology, History and Physical Examination - [71]
Siri B, D'Alessandro A, Maiorana A et al.. “Adrenocortical function in patients with Single Large Scale Mitochondrial DNA Deletions: a retrospective single centre cohort study.” European journal of endocrinology (2023). PMID: 37815532 ↗
L2bCOHORTCited in: Pathophysiology - [72]
Stancampiano MR, Meroni SLC, Bucolo C et al.. “46,XX Differences of Sex Development outside congenital adrenal hyperplasia: pathogenesis, clinical aspects, puberty, sex hormone replacement therapy and fertility outcomes.” Frontiers in endocrinology (2024). PMID: 38841305 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [73]
Maharaj AV. “Familial Glucocorticoid Deficiency: the changing landscape of an eponymous syndrome.” Frontiers in endocrinology (2023). PMID: 38189052 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [74]
Finkielstain GP, Vieites A, Bergadá I et al.. “Disorders of Sex Development of Adrenal Origin.” Frontiers in endocrinology (2021). PMID: 34987475 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [75]
Betterle C, Presotto F, Furmaniak J. “Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults.” Journal of endocrinological investigation (2019). PMID: 31321757 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [76]
Hellesen A, Bratland E. “The potential role for infections in the pathogenesis of autoimmune Addison's disease.” Clinical and experimental immunology (2019). PMID: 30144040 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [77]
Wei C, Crowne EC. “The hypothalamic-pituitary-adrenal axis in childhood cancer survivors.” Endocrine-related cancer (2018). PMID: 29895525 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Differential Diagnosis - [78]
Flück CE. “MECHANISMS IN ENDOCRINOLOGY: Update on pathogenesis of primary adrenal insufficiency: beyond steroid enzyme deficiency and autoimmune adrenal destruction.” European journal of endocrinology (2017). PMID: 28450305 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [79]
Altieri B, Muscogiuri G, Barrea L et al.. “Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept.” Reviews in endocrine & metabolic disorders (2017). PMID: 28070798 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [80]
Husebye ES, Allolio B, Arlt W et al.. “Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency.” Journal of internal medicine (2014). PMID: 24330030 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Special Populations - [81]
Grabarczyk M, Gorczyca M, Cieślik P et al.. “Addison's Disease in the Course of Recurrent Microangiopathic Antiphospholipid Syndrome-A Clinical Presentation and Review of the Literature.” Medicina (Kaunas, Lithuania) (2022). PMID: 36676628 ↗
L4CASE_REPORTCited in: Pathophysiology - [82]
Medina G, Jiménez-Arellano MP, Muñoz-Solís A et al.. “Primary antiphospholipid syndrome, Addison disease, and adrenal incidentaloma.” Clinical rheumatology (2020). PMID: 32146613 ↗
L4CASE_REPORTCited in: Pathophysiology - [83]
Brachet C, Laemmle A, Cools M et al.. “Insight into the role of TXNRD2 in steroidogenesis through a novel homozygous TXNRD2 splice variant.” European journal of endocrinology (2024). PMID: 39097530 ↗
L4CASE_REPORTCited in: Pathophysiology - [84]
Ghaddhab C, Capper CP, Larrivée-Vanier S et al.. “Severe Aldosterone Synthase Deficiency in a 9-Day-Old Lebanese Boy: The Importance of Functional Studies to Establish Pathogenicity of Seemingly Benign Variants in CYP11B2.” Hormone research in paediatrics (2025). PMID: 38316111 ↗
L4CASE_REPORTCited in: Pathophysiology - [85]
Gagnon C, Hurst ACE, Ashraf AP. “Adrenal Insufficiency in Peroxisomal Disorders: A Single Institution Case Series.” Hormone research in paediatrics (2023). PMID: 36649687 ↗
L4CASE_REPORTCited in: Pathophysiology - [86]
Montoya-Williams D, Mowitz M. “Cholestasis and Hepatic Iron Deposition in an Infant With Complex Glycerol Kinase Deficiency.” Pediatrics (2017). PMID: 28759390 ↗
L4CASE_REPORTCited in: Pathophysiology - [87]
Wentworth BJ, Siragy HM. “Adrenal Insufficiency in Cirrhosis.” Journal of the Endocrine Society (2022). PMID: 36033971 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [88]
Nisticò D, Bossini B, Benvenuto S et al.. “Pediatric Adrenal Insufficiency: Challenges and Solutions.” Therapeutics and clinical risk management (2022). PMID: 35046659 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [89]
Dineen R, Stewart PM, Sherlock M. “Factors impacting on the action of glucocorticoids in patients receiving glucocorticoid therapy.” Clinical endocrinology (2019). PMID: 30120786 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [90]
Hellesen A, Bratland E, Husebye ES. “Autoimmune Addison's disease - An update on pathogenesis.” Annales d'endocrinologie (2018). PMID: 29631795 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [91]
Russell G, Kalafatakis K, Durant C et al.. “Ultradian hydrocortisone replacement alters neuronal processing, emotional ambiguity, affect and fatigue in adrenal insufficiency: The PULSES trial.” Journal of internal medicine (2024). PMID: 37857352 ↗
L1bRCTCited in: History and Physical Examination, Prognosis and Long-term Outcomes - [92]
Kumar S, Pandit R, Sarathi V et al.. “46, XY under-virilization and NR5A1 variants: Monocentric Indian experience and systematic review.” Annales d'endocrinologie (2025). PMID: 40280302 ↗
L2aSR_OBSCited in: History and Physical Examination - [93]
Ovakimyan A, Patel NA, Brown NJ et al.. “Acute Mania and Psychosis in the Context of Primary Adrenal Insufficiency: A Systematic Review of the Literature.” Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology (2023). PMID: 37026774 ↗
L2aSR_OBSCited in: History and Physical Examination - [94]
Lu W, Zhang T, Zhang L et al.. “Clinical characteristics of a male child with non-classic lipoid congenital adrenal hyperplasia and literature review.” Frontiers in endocrinology (2022). PMID: 36407315 ↗
L4CASE_REPORTCited in: History and Physical Examination, Prevention and Screening - [95]
Pons Fernández N, Moriano Gutiérrez A, Taberner Pazos B et al.. “A novel mutation in the NNT gene causing familial glucocorticoid deficiency, with a literature review.” Annales d'endocrinologie (2024). PMID: 37352919 ↗
L4CASE_REPORTCited in: History and Physical Examination - [96]
Bonataki M, Dikaiakou E, Anastasopoulou P et al.. “An 11-year-old girl with Autoimmune Polyglandular Syndrome (APS) type 2: a case report and review of literature.” Journal of pediatric endocrinology & metabolism : JPEM (2023). PMID: 36919239 ↗
L4CASE_REPORTCited in: History and Physical Examination - [97]
Giannakopoulos A, Sertedaki A, Efthymiadou A et al.. “Addison's disease without hyperpigmentation in pediatrics: pointing towards specific causes.” Hormones (Athens, Greece) (2023). PMID: 36348260 ↗
L4CASE_REPORTCited in: History and Physical Examination - [98]
Kelestemur E, Yarar MH, Gurpinar Tosun B et al.. “Primary adrenal insufficiency in patients with CPOX gene mutations.” European journal of endocrinology (2025). PMID: 40296768 ↗
L4CASE_REPORTCited in: History and Physical Examination - [99]
Touzon R. “Eating Disorder vs Addison's Disease: A Case Report and Review of the Published Case Reports.” Actas espanolas de psiquiatria (2025). PMID: 40356001 ↗
L4CASE_REPORTCited in: History and Physical Examination - [100]
Pizza A, Picillo E, Onore ME et al.. “Xp21 contiguous gene deletion syndrome presenting as Duchenne muscular dystrophy and glycerol kinase deficiency associated with intellectual disability: case report and review literature.” Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology (2023). PMID: 37091526 ↗
L4CASE_REPORTCited in: History and Physical Examination - [101]
Javaid R, Sinaii N, Kollender S et al.. “Course of COVID-19 infection in patients with congenital adrenal hyperplasia.” Frontiers in endocrinology (2024). PMID: 38405151 ↗
L5OTHERCited in: History and Physical Examination - [102]
Duan Y, Zheng W, Xia Y et al.. “Genetic and phenotypic spectrum of non-21-hydroxylase-deficiency primary adrenal insufficiency in childhood: data from 111 Chinese patients.” Journal of medical genetics (2023). PMID: 37586839 ↗
L5OTHERCited in: History and Physical Examination - [103]
Zheng W, Duan Y, Xia Y et al.. “Clinical and genetic characteristics of 42 Chinese paediatric patients with X-linked adrenal hypoplasia congenita.” Orphanet journal of rare diseases (2023). PMID: 37237297 ↗
L5OTHERCited in: History and Physical Examination - [104]
Gasco V, Giannelli J, Campioni L et al.. “Benefits of dual-release hydrocortisone treatment on central adiposity and health-related quality of life in secondary adrenal insufficiency.” Journal of endocrinological investigation (2023). PMID: 36251244 ↗
L5OTHERCited in: History and Physical Examination, Differential Diagnosis - [105]
George A, Rallapalli A, Nanda PM et al.. “Clinical and genetic insights into congenital lipoid adrenal hyperplasia: a case series from a tertiary care center in North India.” Journal of pediatric endocrinology & metabolism : JPEM (2025). PMID: 40252005 ↗
L4CASE_REPORTCited in: History and Physical Examination - [106]
Saeedi V, Rahimzadeh N, Ehsanipour F et al.. “Clinical presentation and management challenges of sphingosine-1-phosphate lyase insufficiency syndrome associated with an SGPL1 variant: a case report.” BMC pediatrics (2025). PMID: 39755650 ↗
L4CASE_REPORTCited in: History and Physical Examination - [107]
Mellone S, Bertelli E, Roviglione B et al.. “Co-Occurrence of a Pathogenic HSD3B2 Variant and a Duplication on 10q22.3-q23.2 Detected in Newborn Twins with Salt-Wasting Congenital Adrenal Hyperplasia.” Genes (2022). PMID: 36553457 ↗
L4CASE_REPORTCited in: History and Physical Examination - [108]
Viswanathan RA. “The mask of deficiency: A rare case of facial hyperpigmentation in vitamin B12 deficiency - a case report and review of literature.” Tropical doctor (2026). PMID: 40956928 ↗
L4CASE_REPORTCited in: History and Physical Examination - [109]
Woodcock T, Barker P, Daniel S et al.. “Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: Guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK.” Anaesthesia (2020). PMID: 32017012 ↗
L1cGUIDELINECited in: Differential Diagnosis, Special Populations - [110]
Ospina NS, Al Nofal A, Bancos I et al.. “ACTH Stimulation Tests for the Diagnosis of Adrenal Insufficiency: Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26649617 ↗
L2aSR_OBSCited in: Differential Diagnosis - [111]
Hayashi R, Tamada D, Murata M et al.. “Glucocorticoid Replacement Affects Serum Adiponectin Levels and HDL-C in Patients With Secondary Adrenal Insufficiency.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31290981 ↗
L1bRCTCited in: Differential Diagnosis - [112]
Arima H, Iwama S, Inaba H et al.. “Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society.” Endocrine journal (2019). PMID: 31243183 ↗
L1cGUIDELINECited in: Differential Diagnosis - [113]
Li L, Bensing S, Falhammar H. “Rate of fracture in patients with glucocorticoid replacement therapy: a systematic review and meta-analysis.” Endocrine (2021). PMID: 33846948 ↗
L2aSR_OBSCited in: Differential Diagnosis - [114]
Yang Y, Liu J, Yang K et al.. “Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.” Journal of clinical pharmacology (2021). PMID: 33345342 ↗
L2aSR_OBSCited in: Differential Diagnosis - [115]
Boesen VB, Christoffersen T, Watt T et al.. “PlenadrEMA: effect of dual-release versus conventional hydrocortisone on fatigue, measured by ecological momentary assessments: a study protocol for an open-label switch pilot study.” BMJ open (2018). PMID: 29362269 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis - [116]
Vulto A, Bergthorsdottir R, van Faassen M et al.. “Residual endogenous corticosteroid production in patients with adrenal insufficiency.” Clinical endocrinology (2019). PMID: 31059146 ↗
L1bRCTCited in: Differential Diagnosis - [117]
Wierman ME, Kiseljak-Vassiliades K. “Should Dehydroepiandrosterone Be Administered to Women?” The Journal of clinical endocrinology and metabolism (2022). PMID: 35254428 ↗
L4CASE_REPORTCited in: Differential Diagnosis, Prognosis and Long-term Outcomes - [118]
Lee JH, Torpy DJ. “Adrenal insufficiency in pregnancy: Physiology, diagnosis, management and areas for future research.” Reviews in endocrine & metabolic disorders (2023). PMID: 35816262 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Special Populations - [119]
Iwama S, Kobayashi T, Arima H. “Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.” Endocrinology and metabolism (Seoul, Korea) (2021). PMID: 33934588 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [120]
Husebye ES, Pearce SH, Krone NP et al.. “Adrenal insufficiency.” Lancet (London, England) (2021). PMID: 33484633 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [121]
Martin-Grace J, Dineen R, Sherlock M et al.. “Adrenal insufficiency: Physiology, clinical presentation and diagnostic challenges.” Clinica chimica acta; international journal of clinical chemistry (2020). PMID: 32035851 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [122]
Raff H, Sharma ST, Nieman LK. “Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.” Comprehensive Physiology (2014). PMID: 24715566 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [123]
Corsello SM, Barnabei A, Marchetti P et al.. “Endocrine side effects induced by immune checkpoint inhibitors.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23471977 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [124]
Tang JL, Huang J, Wang X et al.. “[The clinical reports on adrenal insufficiency of patients with advanced solid tumors accepting anti-PD-1 antibody, SHR-1210 therapy].” Zhonghua zhong liu za zhi [Chinese journal of oncology] (2019). PMID: 31216835 ↗
L2bTRIAL_NONRANDOMCited in: Differential Diagnosis - [125]
Shaikh S, Nagendra L, Shaikh S et al.. “Adrenal Failure: An Evidence-Based Diagnostic Approach.” Diagnostics (Basel, Switzerland) (2023). PMID: 37238296 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [126]
Bhattacharya S, Krishnamurthy A, Gopalakrishnan M et al.. “Endocrine and Metabolic Manifestations of Snakebite Envenoming.” The American journal of tropical medicine and hygiene (2020). PMID: 32602439 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [127]
Haissaguerre M, Hescot S, Bertherat J et al.. “Expert opinions on adrenal complications in immunotherapy.” Annales d'endocrinologie (2018). PMID: 30149891 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [128]
Chabre O, Goichot B, Zenaty D et al.. “Group 1. Epidemiology of primary and secondary adrenal insufficiency: Prevalence and incidence, acute adrenal insufficiency, long-term morbidity and mortality.” Annales d'endocrinologie (2017). PMID: 29174931 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [129]
Aulinas A, Webb SM. “Health-related quality of life in primary and secondary adrenal insufficiency.” Expert review of pharmacoeconomics & outcomes research (2014). PMID: 25252879 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [130]
Tucci V, Sokari T. “The clinical manifestations, diagnosis, and treatment of adrenal emergencies.” Emergency medicine clinics of North America (2014). PMID: 24766944 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [131]
Singha A, Mukhopadhyay P, Ghosh S. “Adrenocorticotropic Hormone Measured by Immulite 1000 and Elecsys Assay Platforms in Suspected Cases of Hypocortisolism: A Word of Caution.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 40049330 ↗
L5OTHERCited in: Differential Diagnosis - [132]
Lovato CM, Thévenot T, Borot S et al.. “Decreased maximal cortisol secretion rate in patients with cirrhosis: Relation to disease severity.” JHEP reports : innovation in hepatology (2021). PMID: 34027338 ↗
L5OTHERCited in: Differential Diagnosis - [133]
Ngaosuwan K, Johnston DG, Godsland IF et al.. “Cardiovascular Disease in Patients With Primary and Secondary Adrenal Insufficiency and the Role of Comorbidities.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33585930 ↗
L5OTHERCited in: Differential Diagnosis - [134]
Cauldwell M, Steer PJ, Ahsan M et al.. “Pregnancy Outcomes in Women With Primary Adrenal Insufficiency: Data From a Multicentre Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40159596 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations - [135]
Wijaya M, Ma H, Zhang J et al.. “Aldosterone signaling defect in young infants: single-center report and review.” BMC endocrine disorders (2021). PMID: 34243750 ↗
L2bTRIAL_NONRANDOMCited in: Prognosis and Long-term Outcomes - [136]
Fouatih K, Trouvin MA, Lambert AS et al.. “Continuous subcutaneous hydrocortisone infusion in pediatric primary adrenal insufficiency: a cohort study.” Endocrine connections (2026). PMID: 41493139 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [137]
Dalakas K, Allosso F, Basile C et al.. “Increased mortality in primary adrenal insufficiency: a systematic review and meta-analysis.” European journal of endocrinology (2025). PMID: 40966723 ↗
L2aSR_OBSCited in: Prognosis and Long-term Outcomes - [138]
Pal N, Banu HN, Chakraborty M et al.. “Current perspective of adrenal histoplasmosis in India: A prospective study in a tertiary care hospital, Eastern India.” Indian journal of medical microbiology (2023). PMID: 36272878 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [139]
Ahmadi I, Estabraghnia Babaki H, Maleki M et al.. “Changes in Physiological Levels of Cortisol and Adrenocorticotropic Hormone upon Hospitalization Can Predict SARS-CoV-2 Mortality: A Cohort Study.” International journal of endocrinology (2022). PMID: 35251166 ↗
L2bCOHORTCited in: Prognosis and Long-term Outcomes - [140]
Teti C, Bezante G, Gatto F et al.. “An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report.” BMC endocrine disorders (2023). PMID: 37246209 ↗
L4CASE_REPORTCited in: Prognosis and Long-term Outcomes - [141]
Shagjaa T, Sanga V, Rossi GP. “Skin Hyperpigmentation Due to Post-Surgical Adrenal Insufficiency Regressed with the Dexamethasone Treatment.” Journal of clinical medicine (2022). PMID: 36143026 ↗
L4CASE_REPORTCited in: Prognosis and Long-term Outcomes - [142]
Dong J, Hahner S, Bancos I et al.. “Clinical features, investigation, and management of Addison's disease.” The lancet. Diabetes & endocrinology (2026). PMID: 41587556 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [143]
Prete A, Theiler-Schwetz V, Arlt W et al.. “Effects of modified release hydrocortisone on restoration of early morning cortisol, quality of life, and fatigue in adrenal insufficiency (The CHAMPAIN study): a randomised, double-blind, double-dummy, cross-over study comparing Chronocort and Plenadren.” EClinicalMedicine (2026). PMID: 41552007 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [144]
Capalbo D, Illiano S, Vasaturo S et al.. “A practical approach to diagnosis and treatment in children with primary adrenal insufficiency.” European journal of endocrinology (2025). PMID: 41218652 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [145]
Lee J, Hamidi O, Simon E et al.. “Continuous Subcutaneous Hydrocortisone Infusion in Adrenal Insufficiency: Practical Experience in 33 Subjects.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 40374113 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [146]
Surani A, Carroll TB. “Autoimmune Primary Adrenal Insufficiency: Understanding the Past, Present, and Future.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 40294795 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [147]
Stergianos S, Everhov ÅH, Söderling J et al.. “Income and work loss in patients with Addison's disease: a nationwide population-based study.” European journal of endocrinology (2025). PMID: 39980335 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [148]
Tomasello L, Coppola A, Pizzolanti G et al.. “Dual-release hydrocortisone treatment improves serum and peripheral blood mononuclear cell inflammatory and immune profiles in patients with autoimmune primary adrenal insufficiency.” Frontiers in immunology (2025). PMID: 39917303 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [149]
Iwama S, Kobayashi T, Arima H. “Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.” Nature reviews. Endocrinology (2025). PMID: 39779950 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Long-term Outcomes - [150]
Zdrojowy-Wełna A, Stańska A, Halupczok-Żyła J et al.. “Health-Related Quality of Life in Patients with Primary Adrenal Insufficiency.” Journal of clinical medicine (2023). PMID: 38068288 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [151]
Nowotny HF, Marchant Seiter T, Ju J et al.. “Major immunophenotypic abnormalities in patients with primary adrenal insufficiency of different etiology.” Frontiers in immunology (2023). PMID: 38045693 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [152]
Bioletto F, Barale M, Parasiliti-Caprino M et al.. “Bone safety of dual-release hydrocortisone in patients with autoimmune primary adrenal insufficiency.” Frontiers in endocrinology (2023). PMID: 37766685 ↗
L5OTHERCited in: Prognosis and Long-term Outcomes - [153]
Bornstein SR, Allolio B, Arlt W et al.. “Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26760044 ↗
L1cGUIDELINECited in: Special Populations - [154]
Ramasamy A, Madhan B. “Steroid supplementation before minor oral surgical procedures in patients taking long-term glucocorticoids: A triple-blinded, randomized, placebo-controlled trial.” Journal of the American Dental Association (1939) (2023). PMID: 36966086 ↗
L1bRCTCited in: Special Populations - [155]
Schiavone D, Ballo M, Filardo M et al.. “Total adrenalectomy versus subtotal adrenalectomy for bilateral pheochromocytoma: meta-analysis.” BJS open (2023). PMID: 37945270 ↗
L2aSR_OBSCited in: Special Populations - [156]
Schneiderman M, Czuzoj-Shulman N, Spence AR et al.. “Maternal and neonatal outcomes of pregnancies in women with Addison's disease: a population-based cohort study on 7.7 million births.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 27981742 ↗
L2bCOHORTCited in: Special Populations - [157]
Chantzichristos D, Persson A, Eliasson B et al.. “Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study.” European journal of endocrinology (2017). PMID: 27928991 ↗
L2bCOHORTCited in: Special Populations - [158]
Świątkowska-Stodulska R, Berlińska A, Stefańska K et al.. “Endocrine Autoimmunity in Pregnancy.” Frontiers in immunology (2022). PMID: 35844617 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [159]
Ko E, Panchal N. “Pigmented Lesions.” Dermatologic clinics (2020). PMID: 32892857 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [160]
Zhu J, Eichler F, Biffi A et al.. “The Changing Face of Adrenoleukodystrophy.” Endocrine reviews (2020). PMID: 32364223 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Prevention and Screening - [161]
Charmandari E, Nicolaides NC, Chrousos GP. “Adrenal insufficiency.” Lancet (London, England) (2014). PMID: 24503135 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [162]
Grossman A, Johannsson G, Quinkler M et al.. “Therapy of endocrine disease: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe.” European journal of endocrinology (2013). PMID: 24031090 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [163]
Elradi W, Innayat S, Hanafy A et al.. “Bilateral adrenal infarction and secondary haemorrhage in pregnancy: implications of factor V Leiden heterozygosity. A review of the literature and a case report.” Clinical medicine (London, England) (2025). PMID: 39864558 ↗
L4CASE_REPORTCited in: Special Populations - [164]
Margulies SL, Corrigan K, Bathgate S et al.. “Addison's disease in pregnancy: Case report, management, and review of the literature.” Journal of neonatal-perinatal medicine (2020). PMID: 31744021 ↗
L4CASE_REPORTCited in: Special Populations - [165]
Hatabu N, Amano N, Mori J et al.. “Pubertal Development and Pregnancy Outcomes in 46,XX Patients With Nonclassic Lipoid Congenital Adrenal Hyperplasia.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30476142 ↗
L4CASE_REPORTCited in: Special Populations - [166]
Bensing S, Giordano R, Falorni A. “Fertility and pregnancy in women with primary adrenal insufficiency.” Endocrine (2020). PMID: 32472424 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [167]
Ravel C, Hyon C, Siffroi JP et al.. “Are human male patients with DAX1/NR0B1 mutations infertile?” Annales d'endocrinologie (2014). PMID: 24751136 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [168]
Kamoun M, Mnif MF, Charfi N et al.. “Adrenal diseases during pregnancy: pathophysiology, diagnosis and management strategies.” The American journal of the medical sciences (2014). PMID: 23514671 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [169]
Ron HA, Scobell R, Strong A et al.. “Congenital adrenal calcifications as the first clinical indication of sphingosine lyase insufficiency syndrome: A case report and review of the literature.” American journal of medical genetics. Part A (2022). PMID: 35972040 ↗
L4CASE_REPORTCited in: Special Populations, Prevention and Screening - [170]
Laakso S, Holopainen E, Betterle C et al.. “Pregnancy Outcome in Women With APECED (APS-1): A Multicenter Study on 43 Females With 83 Pregnancies.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34570215 ↗
L5OTHERCited in: Special Populations - [171]
Mouri H, Jo T, Matsui H et al.. “Impact of glucocorticoid supplementation on reducing perioperative complications in patients on long-term glucocorticoid medication: A propensity score analysis using a nationwide inpatient database.” American journal of surgery (2020). PMID: 32067706 ↗
L5OTHERCited in: Special Populations - [172]
Neumann HPH, Tsoy U, Bancos I et al.. “Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy.” JAMA network open (2019). PMID: 31397861 ↗
L5OTHERCited in: Special Populations - [173]
Pané A, Ruiz S, Orois A et al.. “Primary adrenal insufficiency due to hereditary apolipoprotein AI amyloidosis: endocrine involvement beyond hypogonadism.” Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2018). PMID: 29446975 ↗
L5OTHERCited in: Special Populations - [174]
Morelli V, Minelli L, Eller-Vainicher C et al.. “Predictability of hypoadrenalism occurrence and duration after adrenalectomy for ACTH-independent hypercortisolism.” Journal of endocrinological investigation (2018). PMID: 29151238 ↗
L5OTHERCited in: Special Populations - [175]
Shi Y, Shen M, Zheng X et al.. “Immune Checkpoint Inhibitor-Induced Adrenalitis and Primary Adrenal Insufficiency: Systematic Review and Optimal Management.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2021). PMID: 33554872 ↗
L2aSR_OBSCited in: Prevention and Screening - [176]
Pham-Dobor G, Hanák L, Hegyi P et al.. “Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III.” Journal of endocrinological investigation (2020). PMID: 32227311 ↗
L2aSR_OBSCited in: Prevention and Screening - [177]
Hataya Y, Kurata M, Murabe K et al.. “Effects of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol levels in patients with metastatic renal cell carcinoma: a retrospective study.” BMC endocrine disorders (2025). PMID: 41188808 ↗
L2bCOHORTCited in: Prevention and Screening - [178]
Barnabei A, Senes P, Scoppola A et al.. “Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic.” Cancers (2022). PMID: 35158860 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [179]
Paschou SA, Stefanaki K, Psaltopoulou T et al.. “How we treat endocrine complications of immune checkpoint inhibitors.” ESMO open (2021). PMID: 33399077 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [180]
Hoekstra M. “Identification of scavenger receptor BI as a potential screening candidate for congenital primary adrenal insufficiency in humans.” American journal of physiology. Endocrinology and metabolism (2020). PMID: 32369415 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [181]
Maharaj A, Kwong R, Williams J et al.. “A retrospective analysis of endocrine disease in sphingosine-1-phosphate lyase insufficiency: case series and literature review.” Endocrine connections (2022). PMID: 35904228 ↗
L4CASE_REPORTCited in: Prevention and Screening - [182]
Jayant SS, Gupta R, Agrawal K et al.. “Triple A (Allgrove) syndrome due to AAAS gene mutation with a rare association of amyotrophy.” Hormones (Athens, Greece) (2021). PMID: 32700293 ↗
L4CASE_REPORTCited in: Prevention and Screening - [183]
Fierabracci A, Lanzillotta M, Vorgučin I et al.. “Report of two siblings with APECED in Serbia: is there a founder effect of c.769C>T AIRE genotype?” Italian journal of pediatrics (2021). PMID: 34078422 ↗
L4CASE_REPORTCited in: Prevention and Screening - [184]
Ferré EMN, Schmitt MM, Lionakis MS. “Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy.” Frontiers in pediatrics (2021). PMID: 34790633 ↗
L5REVIEW_NARRATIVECited in: Prevention and Screening - [185]
Sjøgren T, Bratland E, Røyrvik EC et al.. “Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies.” Journal of autoimmunity (2022). PMID: 36191466 ↗
L5OTHERCited in: Prevention and Screening - [186]
Fichna M, Małecki PP, Młodzikowska M et al.. “Increased risk of endocrine autoimmunity in first-degree relatives of patients with autoimmune Addison's disease.” European journal of endocrinology (2020). PMID: 32487775 ↗
L5OTHERCited in: Prevention and Screening - [187]
Baioumi A, Darma K, Selvarajan L et al.. “Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a case series and experience from a UK tertiary paediatric hospital.” Journal of pediatric endocrinology & metabolism : JPEM (2026). PMID: 41712317 ↗
L4CASE_REPORTCited in: Prevention and Screening - [188]
Anik M, Erdogan D, Baris T et al.. “Positive neonatal screening test for congenital adrenal hyperplasia in a case with 3β-hydroxysteroid dehydrogenase type 2 deficiency.” Journal of pediatric endocrinology & metabolism : JPEM (2026). PMID: 41111433 ↗
L4CASE_REPORTCited in: Prevention and Screening - [189]
Kaneto H, Isobe H, Sanada J et al.. “A Male Subject with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Which Was Diagnosed at 31 Years Old due to Infertility.” Diagnostics (Basel, Switzerland) (2023). PMID: 36766610 ↗
L4CASE_REPORTCited in: Prevention and Screening - [190]
Tao N, Liu X, Chen Y et al.. “Delayed diagnosis of complex glycerol kinase deficiency in a Chinese male infant: a case report.” BMC pediatrics (2022). PMID: 36050749 ↗
L4CASE_REPORTCited in: Prevention and Screening - [191]
Bischoff J, Fries C, Heer A et al.. “It's Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia.” Journal of the Endocrine Society (2022). PMID: 35356006 ↗
L4CASE_REPORTCited in: Prevention and Screening